Document:

Exhibit

EXHIBIT B
FORM OF SHAREHOLDERS AGREEMENT
This Shareholders Agreement (this “Agreement”) is dated and effective as of [-] between and among ICU Medical, Inc. a Delaware corporation (the “Company”), and Pfizer Inc., a Delaware corporation (the “Shareholder”).  The Company and the Shareholder are referred to in this Agreement individually as a “Party” and collectively as the “Parties.”
RECITALS
WHEREAS, the Company and the Shareholder are parties to a Stock and Asset Purchase Agreement dated as of October 6, 2016 (the “Purchase Agreement”), pursuant to which the Company will acquire the Business (as defined in the Purchase Agreement) from the Shareholder and its Affiliates in exchange for cash and the issuance by the Company of shares of Common Stock to the Shareholder;
WHEREAS, the transactions contemplated by the Purchase Agreement have been consummated as of the date of this Agreement and, pursuant to the Purchase Agreement, the Company has issued to the Shareholder an aggregate of [ - ] shares of Common Stock (the “Initial Shares”), representing approximately [ - ]% (the “Initial Share Percentage”) of the total outstanding shares of Common Stock as of immediately prior to the consummation of the transactions contemplated by the Purchase Agreement;
WHEREAS, the Parties are entering into this Agreement for the purposes of setting forth their agreement and understanding relating to the ownership of Shares by the Shareholder and certain other matters; and
WHEREAS, the execution and delivery of this Agreement is a condition to the obligations of the Parties to consummate the transactions contemplated by the Purchase Agreement.
AGREEMENT
NOW, THEREFORE, in consideration of the foregoing and their respective representations, warranties, covenants and agreements set forth in this Agreement, and intending to be legally bound hereby, the Parties agree as follows:
ARTICLE 1
Definitions
Section 1.1.    Definitions. In addition to the terms defined elsewhere in this Agreement, the following terms have the meanings set forth in this Section 1.1:
“Affiliate” (including, with a correlative meaning, “affiliated”) means, when used with respect to a specified Person, a Person that directly or indirectly, through one or more intermediaries, Controls, is Controlled by or is under common Control with such specified Person.

US-DOCS\70827213.10

“Anti-Corruption Laws” means all applicable anti-bribery and anti-corruption laws, including the Foreign Corrupt Practices Act and the United Kingdom’s Bribery Act 2010.
“Beneficially Own”, “Beneficial Owner” and “Beneficial Ownership” mean, with respect to any securities, having “beneficial ownership” of such securities for purposes of Rule 13d-3 or 13d-5 under the Exchange Act. In addition, a Person shall be deemed to be the Beneficial Owner of, and shall be deemed to Beneficially Own and have Beneficial Ownership of, any securities which are the subject of, or the reference securities for, or that underlie, any Derivative Instrument of such Person, with the number of securities Beneficially Owned being the notional or other number of securities specified in the documentation evidencing the Derivative Instrument as being subject to be acquired upon the exercise or settlement of such Derivative Instrument or as the basis upon which the value or settlement amount of such Derivative Instrument is to be calculated in whole or in part or, if no such number of securities is specified in such documentation, as determined by the Board of Directors in its sole discretion to be the number of securities to which the Derivative Instrument relates.
“Blackout Period” has the meaning set forth in Section 5.2.
“Board of Directors” means the board of directors of the Company.
“Business Day” means any day except any Saturday, any Sunday, any day which is a federal legal holiday in the United States or any day on which banking institutions in the State of New York are authorized or required by Law or other governmental action to close.
“Company Competitor” means those competitors of the Company identified on Schedule I to this Agreement, as such Schedule I is supplemented or amended from time to time to add successors thereto or acquirers thereof, in each case with the consent of the Shareholder, not to be unreasonably withheld, conditioned or delayed.
“Common Stock” means the shares of common stock of the Company, par value $0.10 per share.
“Contract” means any contract, agreement, instrument, undertaking, indenture, commitment, loan, license, settlement, consent, note or other legally binding obligation (whether or not in writing).
“Control”, “Controlled” and “Controlling” mean, when used with respect to any specified Person, the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of such Person, whether through the ownership of voting securities or other interests, by Contract or otherwise, and the terms “Controlled by” and “under common Control with” shall be construed accordingly.
“Current Directors” means directors serving on the Board of Directors as of the date of this Agreement.

-2-

US-DOCS\70827213.10

 “Derivative Instrument” means any and all derivative securities (as defined under Rule 16a­1 under the Exchange Act) that increase in value as the value of any Equity Securities of the Company increases, including a long convertible security, a long call option and a short put option position, in each case, regardless of whether (a) such derivative security conveys any voting rights in any Equity Security, (b) such derivative security is required to be, or is capable of being, settled through delivery of any Equity Security or (c) other transactions hedge the value of such derivative security.
“Equity Right” means, with respect to any Person, any security (including any debt security or hybrid debt­equity security) or obligation convertible into or exercisable or exchangeable for, or giving any Person any right to subscribe for or acquire, or any options, calls, warrants, restricted shares, restricted shares units, deferred share awards, share units, “phantom” awards, dividend equivalents, participations, interests, rights or commitments relating to, or any share appreciation right or other instrument the value of which is determined in whole or in part by reference to the market price or value of, shares of capital stock or earnings of such Person.
“Equity Securities” means (a) Shares or other capital stock or equity interests or equity-linked interests of the Company and (b) Equity Rights that are directly or indirectly exercisable or exchangeable for or convertible into Shares or other capital stock or equity interests or equity-linked interests of the Company. 
“Exchange Act” means the United States Securities Exchange Act of 1934 and the rules and regulations promulgated thereunder. 
“FINRA” means the Financial Industry Regulatory Authority.
“GAAP” means generally accepted accounting principles in the United States.
“Governmental Authority” means any (a) nation, region, state, county, city, town, village, district or other jurisdiction, (b) federal, state, local, municipal, foreign or other government, (c) department, agency or instrumentality of a federal, state, local, municipal, foreign or other government, including any state-owned or state controlled instrumentality of a foreign or other government, (d) governmental or quasi-governmental entity of any nature (including any governmental agency, branch, department or other entity and any court or other tribunal), (e) international or multinational organization formed by states, governments or other international organizations, (f) organization that is designated by executive order pursuant to Section 1 of the United States International Organizations Immunities Act (22 U.S.C. 288 of 1945), as amended, and the rules and regulations promulgated thereunder or (g) other body (including any industry or self-regulating body) exercising, or entitled to exercise, any administrative, executive, judicial, legislative, police or regulatory authority or power of any nature.
“Group” has the meaning assigned to such term in Section 13(d)(3) of the Exchange Act.

-3-

US-DOCS\70827213.10

“Group Member” means, with respect to any specified Person, any Affiliate of the specified Person that is, directly or indirectly, Controlled by the specified Person and includes any Person with respect to which the specified Person is a direct or indirect Subsidiary.
“Hedging Arrangement” means any transaction or arrangement, including through the creation, purchase or sale of any security, including any security-based swap, swap, cash-settled option, forward sale agreement, exchangeable note, total return swap or other derivative, in each case, the effect of which is to hedge the risk of owning Equity Securities.
“Incumbent Directors” means (a) the Current Directors, (b) new directors nominated or appointed by a majority of the Current Directors and (c) other directors nominated or appointed by a majority of the Current Directors and other Incumbent Directors.
“Law” means any supranational, international, national, federal, state, provincial, local or similar law (including common law), statute, code, order, ordinance, rule, regulation, treaty (including any tax treaty), license, permit, authorization, approval, consent, decree, injunction, binding judicial or administrative interpretation, in each case enacted, promulgated issued or entered by a Governmental Authority.
“Lock-Up Period” means the period from the date of this Agreement until the earlier of the date (x) of the expiration of the Term (as defined in the Transitional Services Agreement dated the date hereof between [the Shareholder] and [the Company]) and (y) that is eighteen (18) months following the date of this Agreement.
“Permitted Transferee” means the Shareholder and any  direct or indirect wholly owned Subsidiary of the Shareholder; provided that if any such transferee of Shares ceases to be  a direct or indirect wholly owned Subsidiary of the Shareholder, (a) such transferee shall, and the Shareholder shall procure that such transferee shall, immediately Transfer back the transferred Shares to the applicable transferor, or, if such transferor by that time is no longer a Permitted Transferee, to the Shareholder, as if such Transfer of such Shares had not taken place ab initio, and (b) the Company shall no longer, and shall instruct its transfer agent and other third parties to no longer, record or recognize such Transfer of such Shares on the shareholders’ register of the Company.
“Person” means an individual, corporation, limited liability company, general or limited partnership, joint venture, association, trust, unincorporated organization, Governmental Authority, other entity or Group.
“Prohibited Transferee” means  any Person who, to the actual knowledge of the Shareholder (with respect to clauses (ii) and (iii), based solely upon publicly available information), is (i) a Company Competitor, (ii) a Person that has filed or is part of a “group” (as defined in Section 13(d) of the Exchange Act) that has filed a Schedule 13D with the SEC in respect of any class of equity securities of the Company, or (iii) a Person who at the time of such Transfer Beneficially Owns more than 5% of the Voting Securities.

-4-

US-DOCS\70827213.10

“Registrable Securities” means (a) the Initial Shares, (b) any shares of Common Stock issued or issuable with respect to the Initial Shares on or after the date of this Agreement by way of a share dividend, distribution or share split or in connection with a reclassification, exchange, readjustment or combination of shares, recapitalization, merger, consolidation, other reorganization or similar events and (c) any other shares of Common Stock that are Beneficially Owned by the Shareholder.  As to any particular Registrable Securities, such securities shall cease to be Registrable Securities if (i) a Registration Statement with respect to the sale of such securities has become effective under the Securities Act and such securities have been disposed of pursuant to such effective Registration Statement, (ii) such securities were disposed of pursuant to Rule 144,  (iii) such securities have been Transferred in violation of Section 2.1 of this Agreement or (iv) such securities cease to be outstanding.
“Registration Statement” means any registration statement of the Company that covers any Registrable Securities and all amendments and supplements to any such registration statement, including post-effective amendments, in each case including the prospectus contained therein, all exhibits thereto and all material incorporated by reference therein. 
“Representatives” means, as to any Person, its Affiliates and its and their respective directors, officers, managers, employees, agents, attorneys, accountants, financial advisors and other advisors or representatives.
“Required Registration Statement” means a Registration Statement that covers the Registrable Securities requested to be included therein pursuant to the provisions of Section 5.1 on an appropriate form pursuant to the Securities Act (other than pursuant to Rule 415), and which form is available for the sale of the Registrable Securities in accordance with the intended method or methods of distribution thereof, and all amendments and supplements to such Registration Statement, including post-effective amendments, in each case including the prospectus contained therein, all exhibits thereto and all material incorporated by reference therein.
“Required Shelf Registration Statement” means a Registration Statement that covers the Registrable Securities requested to be included therein pursuant to the provisions of Section 5.1 on an appropriate form or any similar successor or replacement form (in accordance with Section 5.1) pursuant to Rule 415, and which form is available for the sale of the Registrable Securities in accordance with the intended method or methods of distribution thereof, and all amendments and supplements to such Registration Statement, including post-effective amendments, in each case including the prospectus contained therein, all exhibits thereto and all material incorporated by reference therein.
“Rule 144” means Rule 144 promulgated by the SEC pursuant to the Securities Act, as such Rule may be amended from time to time, or any similar rule or regulation hereafter adopted by the SEC having substantially the same effect as such Rule.
“Rule 415” means Rule 415 promulgated by the SEC pursuant to the Securities Act, as such Rule may be amended from time to time, or any similar rule or regulation hereafter adopted by the SEC having substantially the same effect as such Rule.

-5-

US-DOCS\70827213.10

“SEC” means the United States Securities and Exchange Commission.
“Securities Act” means the Securities Act of 1933 and the rules and regulations promulgated thereunder.
“Share Percentage Cap” means the Initial Share Percentage; provided that (a) immediately following any Transfer of Shares by the Shareholder (other than to a Permitted Transferee), the Share Percentage Cap shall be reduced to a percentage equal to (i) the aggregate number of Shares that are Beneficially Owned by the Shareholder and its Group Members immediately following such Transfer of Shares (excluding any Shares for which Beneficial Ownership was acquired in violation of this Agreement prior to such Transfer), divided by (ii) the aggregate number of Shares outstanding immediately following such Transfer of Shares; (b) the Share Percentage Cap shall in no event be less than 5%; and (c) to the extent that any Shares that are deemed to have been Transferred pursuant to any Hedging Arrangement are subsequently returned or released to the Shareholder by a counterparty with respect to such Hedging Arrangement (including as a result of the Shareholder electing cash settlement of such Hedging Arrangement), such Shares shall be treated as if they had not been Transferred by the Shareholder for purposes of this Agreement and the Share Percentage Cap shall be adjusted accordingly.
“Shares” means (a) the Initial Shares, (b) any Equity Securities issued or issuable with respect to the Initial Shares on or after the date of this Agreement by way of a share dividend or share split or in connection with a combination of shares, recapitalization, merger, consolidation or other reorganization and (c) any other Equity Securities held by the Shareholder or any of its Affiliates.
“Standstill Level” means, as of any date, a number of Shares equal to (a) the Share Percentage Cap, multiplied by (b) the number of shares of Common Stock outstanding on such date.
“Standstill Period” means the period beginning on the date hereof and ending on the  first Business Day following the later of the date on which (x) the Shareholder and its Group Members collectively Beneficially Own a number of Shares less than 5% of the then issued and outstanding shares of Common Stock, (y) the Shareholder no longer has the right, under Article VI of this Agreement, to designate an individual for election to the Board of Directors and (z) a director designated by the Shareholder for appointment or election to the Board of Directors ceases serving on the Board of Directors.
“Subsidiary” means, with respect to a specified Person, any corporation or other Person of which securities or other interests having the power to elect a majority of that corporation’s or other Person’s board of directors or similar governing body, or otherwise having the power to direct the business and policies of that corporation or other Person (other than securities or other interests having such power only upon the happening of a contingency that has not occurred) are held by the specified Person or one or more of its Subsidiaries.
“Voting Securities” means the Shares and any other securities of the Company entitled to vote at any general meeting of the Company.

-6-

US-DOCS\70827213.10

Section 1.2.    Additional Defined Terms. For purposes of this Agreement, the following terms have the meanings specified in the indicated Section of this Agreement:
	
		
	Defined Term
	Section

	 
	 

	Agreement   
	Preamble

	Automatic Shelf Registration Statement   
	Section 5.3

	Company   
	Preamble

	Demand Registration   
	Section 5.1

	Initial Share Percentage   
	Recitals

	Initial Shares   
	Recitals

	Lock-Up Period Permitted Transfer   
Other Registrable Securities   
	Section 2.1(a)
Section 5.5(b)(ii)

	Parties   
	Preamble

	Piggyback Registration   
	Section 5.5(a)

	Piggyback Requests   
	Section 5.5(a)

	Purchase Agreement   
	Recitals

	Registration Expenses   
	Section 5.8

	Request   
	Section 5.1

	Requested Information   
	Section 5.9

	Shareholder   
	Preamble

	Shelf Registration   
	Section 5.1

	Transfer   
	Section 2.1

	WKSI   
	Section 5.3

Section 1.3.    Construction.  Unless expressly specified otherwise, whenever used in this Agreement, the terms “Article,” “Exhibit,” “Schedule” and “Section” refer to articles, exhibits, schedules and sections of this Agreement.  Whenever used in this Agreement, the terms “hereby,” “hereof,” “herein” and “hereunder” and words of similar import refer to this Agreement as a whole, including all articles, sections, schedules and exhibits hereto.  Whenever used in this Agreement, the terms “include,” “includes” and “including” mean “include, without limitation,” “includes, without limitation” and “including, without limitation,” respectively.  Whenever the context of this Agreement permits, the masculine, feminine or neuter gender, and the singular or plural number, are each deemed to include the others.  “Days” means calendar days unless otherwise specified.  Unless expressly specified otherwise, all payments to be made in accordance with or under this Agreement shall be made in U.S. Dollars (USD$). References in this Agreement to particular sections of a Law shall be deemed to refer to such sections or provisions as they may be amended after the date of this Agreement. The Parties have participated jointly in the negotiation and drafting of this Agreement and in the event an ambiguity or question of intent or interpretation arises, this Agreement shall be construed as if drafted jointly by the Parties and no presumption or burden of proof shall arise favoring or disfavoring any Party (or any Affiliate thereof) by virtue of the authorship of any of the provisions of this Agreement.

-7-

US-DOCS\70827213.10

ARTICLE 2
 
Transfer Restrictions
Section 2.1.    Restrictions on Transfer. The right of the Shareholder and its Affiliates to directly or indirectly, in any single transaction or series of related transactions, sell, assign, pledge, hypothecate or otherwise transfer (or enter into any Contract or other obligation regarding the future sale, assignment, pledge or transfer of) Beneficial Ownership of (each, a “Transfer”) any Shares is subject to the restrictions set forth in this Article 2, and no Transfer of Shares by the Shareholder or any of its Affiliates may be effected except in compliance with this Article 2 and in accordance with all applicable Laws.  Any attempted Transfer in violation of this Agreement shall be of no effect and null and void, regardless of whether the purported transferee has any actual or constructive knowledge of the Transfer restrictions set forth in this Agreement, and shall not be recorded on the stock transfer books of the Company or any local custodian or transfer agent.
(a)    Until the expiration of the Lock-Up Period, the Shareholder shall not directly or indirectly, in any single transaction or series of related transactions, Transfer any Shares without the prior written consent of the Company, other than the following Transfers (each, a “Lock-Up Period Permitted Transfer”):
(i)    a Transfer of Shares in response to a tender or exchange offer by any Person that has been approved or recommended by the Board of Directors;
(ii)    a Transfer of Shares to the Company or a Subsidiary of the Company; 
(iii)    a Transfer of Shares to a Permitted Transferee, so long as such Permitted Transferee, to the extent it has not already done so, executes a customary joinder to this Agreement, in form and substance reasonably acceptable to the Company, in which such Permitted Transferee agrees to be bound by the terms of this Agreement as if such Permitted Transferee was an original party hereto; 
(i)    a Transfer required by Law; 
(ii)    a Transfer of Shares pursuant to Section 5.5 and meeting the requirements of Section 2.1(c)(ii); and
(vi)    a Transfer of Shares in connection with which the Shareholder’s rights under this Agreement are assigned to the Transferee pursuant to Section 7.6(b)(i).
(b)    Following the Lock-Up Period, the Shareholder shall be entitled to Transfer any Shares in its sole discretion, provided that Shareholder shall not directly or indirectly, in any single transaction or series of related transactions, Transfer any Shares: 
(i)    other than in accordance with all applicable Laws and the other terms and conditions of this Agreement; or

-8-

US-DOCS\70827213.10

(ii)    to a Prohibited Transferee (except in a Non-Prohibited Transfer).
Nothing in this Agreement shall prevent the Shareholder or its Representatives from entering into discussions with the Company or one or more financial institutions in connection with an offering effected pursuant to Section 5.4 and 5.5 after the end of the Lock-up Period, provided that such discussions are not publicly disclosed. 
(c)    A “Non-Prohibited Transfer” means, in each case, so long as such Transfer is in accordance with applicable Law:
(i)    any Lock-Up Period Permitted Transfer;
(ii)    a Transfer of Shares effected through an offering constituting a “public offering” as defined or interpreted in IM-5635-3 under Rule 5635(d) of the Nasdaq Stock Market, pursuant to an exercise of the registration rights provided in Article 5;
(iii)    a Transfer of Shares effected through a “brokers’ transaction” as defined in Rule 144(g) executed on a securities exchange or over­the-counter market by a securities broker-dealer acting as agent for the Shareholder (so long as such Transfer is not directed by the Shareholder to be made to a particular counterparty or counterparties); 
(iv)    a Transfer of Shares to a counterparty in connection with a Hedging Arrangement, including any related Transfer of Shares or other Equity Securities by any such counterparty to any other Person (so long as such Transfer by such counterparty is not at the express direction of the Shareholder and the counterparty is not a Prohibited Transferee);
(v)    a Transfer of Shares in any underwritten offering.
(d)    Notwithstanding anything to the contrary contained herein, the Shareholder shall at no time Transfer, or cause or permit the Transfer of, any Shares, if such Transfer would violate any applicable Law or in connection with any “tender offer” (as such term is used in Regulation 14D under the Exchange Act) not approved or recommended by the Board of Directors.
(e)    Nothing in this Agreement shall prevent the Shareholder or its Representatives from entering into discussions with the Company or one or more financial institutions in connection with  a Lock-Up Period Permitted Transfer or an offering to be effected pursuant to Section 5.4 and 5.5 after the end of the Lock-up Period, provided that such discussions are not publicly disclosed. 
(f)    The entry by the Shareholder into a Hedging Arrangement with respect to Shares shall be deemed to be a Transfer of such Shares for purposes of this Agreement and shall be subject to the provisions of this Section 2.1.
ARTICLE 3
Voting

-9-

US-DOCS\70827213.10

Section 3.1.    Voting Agreement. 
(a)    So long as the aggregate number of Shares that are Beneficially Owned by the Shareholder and its Group Members, as a group, is greater than or equal to 5% of the then issued and outstanding shares of Common Stock, the Shareholder shall cause all of the Voting Securities that are Beneficially Owned by it or any of its Group Members or over which it or any of its Group Members has voting control to be voted (i) in favor of all those persons nominated and recommended to serve as directors of the Company by the Board of Directors or any applicable committee thereof, (ii) with respect to any matter directly relating to remuneration of directors, directors’ insurance or indemnification or release from liability of directors, in a manner proportionally consistent with the vote of shares of Common Stock not Beneficially Owned by the Shareholder or any of its Group Members, and (iii) with respect to any other action, proposal or matter to be voted on by the shareholders of the Company (including through action by written consent), in accordance with the recommendation of the Board of Directors or any applicable committee thereof.  Notwithstanding the foregoing, the Shareholder and its Group Members shall be free to vote at their discretion in connection with any proposal submitted for a vote of the shareholders of the Company in respect of (A) the issuance of Equity Securities in connection with any merger, consolidation or business combination of the Company, (B) any merger, consolidation or business combination of the Company or (C) the sale of all or substantially all the assets of the Company, except in each of clause (A), (B) and (C) where such proposal has not been approved or recommended by the Board of Directors, in which event the preceding sentence shall apply.
(b)    So long as the aggregate number of Shares that are Beneficially Owned by the Shareholder and its Group Members, as a group, is greater than or equal to 5% of the then issued and outstanding shares of Common Stock, with respect to any matter that the Shareholder is required to vote on in accordance with Section 3.1(a), the Shareholder shall cause each Voting Security owned by it or over which it has voting control to be voted by completing the proxy forms distributed by the Company, and not by any other means. The Shareholder shall use reasonable best efforts to deliver the completed proxy form to the Company no later than five (5) Business Days prior to the date of such general meeting of the Company. Upon the written request of the Company, the Shareholder hereby agrees to use reasonable best efforts to take such further action or execute such other instruments as may be reasonably necessary to effectuate the intent of this Section 3.1(b).
ARTICLE 4
Standstill
 Section 4.1.    During the Standstill Period, the Shareholder shall not, directly or indirectly, and shall cause its Representatives (to the extent acting on behalf of the Shareholder) and Group Members directly or indirectly not to, without the prior written consent of, or waiver by, the Company:
(a)    subject to Section 4.2, acquire, offer or seek to acquire, agree to acquire or make a proposal (including any private proposal to the Company or the Board of Directors) to acquire, by purchase or otherwise, any securities (including any Equity Securities or Voting Securities, but excluding debt securities) or Derivative Instruments, or direct or 

-10-

US-DOCS\70827213.10

indirect rights to acquire any securities (including any Equity Securities or Voting Securities, but excluding debt securities) or Derivative Instruments, of the Company or any Subsidiary or Affiliate of the Company, or any securities (including any Equity Securities or Voting Securities, but excluding debt securities) or indebtedness convertible into or exchangeable for any such securities; [provided that the Shareholder may acquire, offer or seek to acquire, agree to acquire or make a proposal to acquire Shares (and any securities (including any Equity Securities or Voting Securities, but excluding debt securities) convertible into or exchangeable for Shares) and Derivative Instruments, if, immediately following such acquisition, the collective Beneficial Ownership of Shares of the Shareholder and its Group Members, as a group, would not exceed the Standstill Level;] provided that nothing in this Agreement, including in this Section 4.1(a), shall prohibit the Shareholder or any of its Group Members from making a non-public offer to the Board of Directors so long as the Shareholder or such Group Member reasonably believes that such offer will not result in the Company or the Shareholder or their Affiliates being required by applicable law to disclose the making of such offer promptly following the making thereof;
(b)    offer, or seek to acquire, or participate in any acquisition of assets or business of the Company and its Subsidiaries; 
(c)    conduct, fund or otherwise become a participant in any “tender offer” (as such term is used in Regulation 14D under the Exchange Act) involving Equity Securities, Voting Securities or any securities convertible into, or exercisable or exchangeable for, Equity Securities or Voting Securities, in each case not approved by the Board of Directors;
(d)    otherwise act in concert with others to seek to control or influence the Board of Directors or shareholders of the Company or its Subsidiaries or Affiliates; provided that nothing in this clause (d) shall preclude the Shareholder or its Representatives from engaging in discussions with the Company or its Representatives or the Shareholder’s designated and/or nominated director to the Board of Directors pursuant to Section 6.2 from engaging in any activities in his or her capacity as such designated and/or nominated director;
(e)    make or join or become a participant (as defined in Instruction 3 to Item 4 of Schedule 14A under the Exchange Act) in (or encourage) any “solicitation” of “proxies” (as such terms are defined in Regulation 14A as promulgated by the SEC), or consent to vote any Voting Securities or any of the voting securities of any Subsidiaries or Affiliates of the Company (including through action by written consent), or otherwise knowingly advise or influence any Person with respect to the voting of any securities of the Company or its Subsidiaries or Affiliates;
(f)    make any public announcement with respect to, or solicit or submit a proposal for, or offer, seek, propose or indicate an interest in (with or without conditions) any merger, consolidation, business combination, “tender offer” (as such term is used in Regulation 14D under the Exchange Act), recapitalization, reorganization, purchase or license of a material portion of the assets, properties, securities or indebtedness of the Company or any 

-11-

US-DOCS\70827213.10

Subsidiary or Affiliate of the Company, or other similar extraordinary transaction involving the Company, any Subsidiary of the Company or any of its securities or indebtedness, or enter into any discussions, negotiations, arrangements, understandings or agreements (whether written or oral) with any other Person regarding any of the foregoing;
(g)    call or seek to call a meeting of shareholders of the Company or initiate any shareholder proposal or meeting agenda item for action of the Company’s shareholders, or seek election or appointment to or to place a representative on the Board of Directors or seek the removal of any director from the Board of Directors;
(h)    form, join, become a member or otherwise participate in a Group (other than with the Shareholder, any of its Group Members or any counterparty (other than a Prohibited Transferee) in connection with a Hedging Arrangement that complies with Section 2.1(c)(iv)) with respect to the securities of the Company or any of its Subsidiaries or Affiliates;
(i)    deposit any Voting Securities in a voting trust or similar Contract or subject any Voting Securities to any voting agreement, pooling arrangement or similar arrangement or Contract, or grant any proxy with respect to any Voting Securities (in each case, other than (i) with the Shareholder or any of its wholly-owned Subsidiaries, (ii) as part of a Hedging Arrangement that complies with Section 2.1(c)(iv) or (iii) in accordance with Section 3.1);
(j)    make any proposal or disclose any plan, or cause or authorize any of its and their directors, officers, employees, agents, advisors and other Representatives to make any proposal or disclose any plan on its or their behalf, inconsistent with the foregoing restrictions;
(k)    knowingly take any action or cause or authorize any of its and their directors, officers, employees, agents, advisors and other Representatives to take any action on its or their behalf, that would reasonably be expected to require the Company or any of its Subsidiaries or Affiliates to publicly disclose any of the foregoing actions or the possibility of a business combination, merger or other type of transaction or matter described in this Section 4.1;
(l)    knowingly advise, assist, arrange or otherwise enter into any discussions or arrangements with any third party with respect to any of the foregoing; or
(m)    directly or indirectly, contest the validity of, any provision of this Section 4.1 (including this subclause) or Section 3.1 (whether by legal action or otherwise).
Section 4.2.    Notwithstanding anything herein to the contrary, the prohibition in Section 4.1(a) shall not apply to the activities of the Shareholder or any of its Group Members in connection with: 

-12-

US-DOCS\70827213.10

(a)    acquisitions made as a result of a stock split, stock dividend, reorganization, recapitalization, reclassification, combination, exchange of shares or other like change approved or recommended by the Board of Directors; or
(b)    acquisitions made in connection with a transaction or series of related transactions in which the Shareholder or any of its Group Members acquires a previously unaffiliated business entity that Beneficially Owns Equity Securities, Voting Securities or Derivative Instruments, or any securities convertible into, or exercisable or exchangeable for, Equity Securities, Voting Securities or Derivative Instruments, at the time of the consummation of such acquisition.
Notwithstanding anything herein to the contrary, the prohibition in Section 4.1(a) shall immediately terminate, and the Shareholder and its Affiliates may engage in any of the activities specified in Section 4.1, in the event that 
(c)    the Company publicly announces that it has entered into an agreement with any Person or group which provides for (i) the acquisition by such person or group of more than 50% of the common stock of the Company or all or a majority of the assets of the Company or (ii) any merger, consolidation or similar business combination, including as a result of a stock split, stock dividend, reorganization, recapitalization, reclassification, combination, exchange of shares or other like change; involving the Company and such person or group (each, a "Third Party Acquisition");
(d)    the Board of Directors recommends that shareholders of the Company tender their shares or vote in favor of a Third Party Acquisition; or
(e)    any person or group (i) acquires Beneficial Ownership of more than 50% of the outstanding Common Stock of the Company, (ii) makes an offer which if fully subscribed would result in such person or group acquiring Beneficial Ownership of more than 50% of the outstanding Common Stock of the Company, or (iii) publicly announces an intention to engage in a Third Party Acquisition, and, in the case of clause (ii) or (iii), the Company does not, within ten (10) Business Days of public announcement thereof by such person or group, publicly oppose and/or recommend to its stockholders that they not accept such offer or support such Third Party Acquisition.
Notwithstanding any of the foregoing, nothing in this Agreement shall restrict (i) any of the Shareholder's Representatives effecting or recommending transactions in securities (A) in the ordinary course of its business as an investment advisor, broker, dealer in securities, market maker, specialist or block positioner and (B) not at the direct or request of the Shareholder or any of its Affiliates, and (ii) the director designated or nominated by the Shareholder from exercising his or her fiduciary duties as a member of the Board of Directors. 
ARTICLE 5
Registration Rights
Section 5.1.    Demand Registration.  At any time and from time to time beginning on the date that the Company files with the SEC its Annual Report on Form 10-K for 

-13-

US-DOCS\70827213.10

the fiscal year ended December 31, 2017, the Shareholder may request in writing (“Request”) that the Company register under the Securities Act all or part of the Registrable Securities that are Beneficially Owned by the Shareholder or its Affiliates (a) on a Registration Statement on Form S­3 or other available form (a “Demand Registration”) or (b) on a Shelf Registration Statement covering any Registrable Securities (or otherwise designating an existing Shelf Registration Statement with the SEC to cover the Registrable Securities) (a “Shelf Registration”), in each case, covering the sale or distribution of the Registrable Securities from time to time by the Shareholder, on a delayed or continuous basis pursuant to Rule 415 of the Securities Act, including by way of underwritten offering, block sale or other distribution plan designated by the Shareholder.  Upon receipt of any Request, the Company shall as promptly as practicable but in any event not later than the date that is thirty (30) calendar days after receipt by the Company of such Request, in accordance with the provisions of this Agreement, file a Registration Statement with the SEC covering all such Registrable Securities, in accordance with the method or methods of distribution thereof elected by the Shareholder.  In the event that any such Request involves a Hedging Arrangement in which the counterparty to the Shareholder uses the Shelf Registration Statement to effect short sales of Registrable Securities, the consent of the Company shall be required in connection with such Request, such consent not to be unreasonably withheld, delayed or conditioned. The Shareholder shall be entitled to make no more than four (4) Requests in any twelve-month period and eight (8) Requests in the aggregate (it being understood that each underwritten offering under this Agreement shall count as a Request, even if such offering is conducted pursuant to a Shelf Registration Statement, unless the Shareholder withdraws its request in the circumstances described in the second sentence of Section 5.6, and each such Request shall be to register an amount of Registrable Securities having an aggregate value of at least $50,000,000.  The Company shall not be obligated to effect a Demand Registration during the sixty (60) calendar day period following the effective date of a Registration Statement pursuant to any other Demand Registration.  Each Request pursuant to this Section 5.1 shall be in writing and shall specify the number of Registrable Securities requested to be registered and the intended method of distribution of such Registrable Securities.  Nothing in this Article 5 shall affect, supersede or otherwise modify any of the restrictions on Transfer set forth in Article 2 or any other provision of this Agreement.
Section 5.2.    Restrictions on Demand Registrations. The Company may (a) postpone the filing or the effectiveness of a Registration Statement requested by the Shareholder or of a supplement or amendment thereto during the regular quarterly period during which directors and executive officers of the Company are not permitted to trade under the insider trading policy of the Company then in effect until the expiration of such quarterly period (but in no event later than two (2) Business Days after the date of the Company’s quarterly earnings announcement) and (b) postpone for up to seventy five (75) calendar days the filing or the effectiveness of a Registration Statement or of a supplement or amendment thereto if the Board of Directors determines in good faith that such Demand Registration or Shelf Registration, as the case may be, would (i) reasonably be expected to materially impede, delay, interfere with or otherwise have a material adverse effect on any material acquisition of assets (other than in the ordinary course of business), merger, consolidation, tender offer, financing or any other material business transaction by the Company or any of its Subsidiaries or (ii) require disclosure of information that has not been, and is otherwise not required to be, disclosed to the public, the premature disclosure of which the Company, after 

-14-

US-DOCS\70827213.10

consultation with outside counsel to the Company, believes would materially and adversely affect the Company (any such period in either clause (a) or (b) to be referred to as a “Blackout Period”). The postponement rights in clause (b) of the first sentence of this Section 5.2 shall not be applicable to the Shareholder for more than a total of one hundred twenty (120) calendar days during any period of twelve (12) consecutive months. 
Section 5.3.    Automatic Shelf Registrations. To the extent that the Company qualifies as a well-known seasoned issuer as defined in Rule 405 under the Securities Act (a “WKSI”) at the time of such Request, the Shareholder may request that the Company file with the SEC an automatic shelf registration statement (as defined in Rule 405 under the Securities Act) on Form S­3 (an “Automatic Shelf Registration Statement”) permitting the public resale of Registrable Securities in accordance with the requirements of the Securities Act and the rules and regulations of the SEC thereunder. The Company shall use its reasonable best efforts and take all actions required or reasonably requested by the Shareholder to maintain the effectiveness of such Automatic Shelf Registration Statement in accordance with the requirements of the Securities Act and the rules and regulations of the SEC thereunder and subject to the Blackout Periods set forth in Section 5.2. At the time any Request for a Demand Registration or Shelf Registration is submitted to the Company on or after the date of this Agreement and, pursuant to such Request, the Shareholder requests, in accordance with this Section 5.3, that the Company file an Automatic Shelf Registration Statement, the Company shall file an Automatic Shelf Registration Statement in accordance with the requirements of the Securities Act and the rules and regulations of the SEC thereunder, which covers the Registrable Securities held by the Shareholder. At the written request of the Shareholder, the Company shall pay the registration fee with respect to a take-down from an Automatic Shelf Registration Statement promptly and, in any event, within the time period required by applicable Law after receiving such written request. So long as the Shareholder is entitled to registration rights pursuant to this Article 5, the Company shall use its reasonable best efforts to remain a WKSI and not to become an ineligible issuer (as defined in Rule 405 under the Securities Act). If, at any time following the filing of an Automatic Shelf Registration Statement when the Company is required to re-evaluate its WKSI status, the Company determines that it is not a WKSI, the Company shall use its reasonable best efforts to post-effectively amend the Automatic Shelf Registration Statement to a Registration Statement or Shelf Registration Statement on Form S-3 or file a new Shelf Registration Statement on Form S-3, have such Shelf Registration Statement declared effective by the SEC and keep such Shelf Registration Statement effective during the period in which such Shelf Registration Statement is required to be kept effective in accordance with this Article 5.
Section 5.4.    Selection of Underwriters; Underwritten Offering. If the Shareholder so notifies the Company in writing, the Company shall use its reasonable best efforts to cause a Demand Registration or Shelf Registration to be in the form of an underwritten offering. In connection with any underwritten Demand Registration or Shelf Registration, the Shareholder shall have the sole right to select the managing underwriters, bookrunners and the non-bookrunning underwriters, subject to such underwriters being nationally recognized investment banks and subject to the prior approval of the Company, which approval shall not be unreasonably withholder, conditioned or delayed. The Shareholder may not participate in any registration under this Agreement which is underwritten unless the Shareholder agrees to sell the Registrable Securities held by the Shareholder on the basis provided in any underwriting agreement with the underwriters 

-15-

US-DOCS\70827213.10

and completes and executes all questionnaires, powers of attorney, indemnities, underwriting agreements and other documents reasonably required under the terms of such underwriting arrangements.
Section 5.5.    Piggyback Registrations. 
(a)    If the Company determines to publicly sell in an underwritten offering or register for sale any of its securities either for its own account or the account of a security holder or holders, other than a registration pursuant to Section 5.1, a registration relating solely to any employee or director equity or equity-based incentive or compensation plan or arrangement or any similar employee or director compensation or benefit plan, a registration relating to the offer and sale of debt securities, a registration relating solely to a corporate reorganization (including by way of merger of the Company or any of its Subsidiaries with any other business) or acquisition of another business, or a registration on any registration form that does not permit secondary sales (a “Piggyback Registration”), the Company shall (i) as soon as reasonably practicable but in no event less than three business days prior to the initial filing of a registration statement in connection with such Piggyback Registration (or two days prior to the date of the commencement of any such offering if such Piggyback Registration is conducted as an underwritten offering) give written notice of its intention to effect such sale or registration to the Shareholder and (ii) subject to Section 5.5(b) and Section 5.5(c), include in such Piggyback Registration and in any underwriting involved therein (whether prior to or following the expiration of the Lock-Up Period) all of such Registrable Securities as are specified in a written request or requests (“Piggyback Requests”) made by the Shareholder received by the Company within ten (10) Business Days after such written notice from the Company is given to the Shareholder. Such Piggyback Requests shall specify the number of Registrable Securities requested to be disposed of by the Shareholder.
(b)    If a Piggyback Registration is an underwritten primary registration on behalf of the Company, and the managing underwriters advise the Company in writing that in their  opinion the aggregate number of securities requested to be included in such registration exceeds the number which can be sold in an orderly manner in such offering without adversely affecting the success of such offering (including an adverse effect on the offering price), the Company shall include in such registration only such securities as the Company is advised by such managing underwriters can be sold without such an effect, which securities shall be included in the following order of priority:
(i)    first, the securities the Company proposes to sell,
(ii)    second, the securities requested to be included in such registration by the holders of Registrable Securities and holders that are contractually entitled to include such securities therein pursuant to those written agreement(s) entered into by the Company prior to the date of this Agreement and identified on Schedule II hereto (the “Other Registrable Securities”), pro rata on the basis of the number of Registrable Securities and Other Registrable Securities requested to be included in such registration, and 
(iii)    third, any other securities requested to be included in such registration. 

-16-

US-DOCS\70827213.10

(c)    If a Piggyback Registration is an underwritten secondary registration on behalf of any holder of Other Registrable Securities, and the managing underwriters advise the Company in writing that in their  opinion the number of securities requested to be included in such registration exceeds the number which can be sold in an orderly manner in such offering without adversely affecting the success of such offering (including an adverse effect on the offering price), the Company shall include in such registration only such securities as the Company is advised by such managing underwriters can be sold without such an effect, which securities shall be included in the following order of priority: (i) first, the Other Registrable Securities requested to be included in such registration, (ii) second, the Registrable Securities requested to be included in such registration and (iii) third, any other securities requested to be included in such registration.
(d)    The Company and any holder of Other Registrable Securities initiating any Piggyback Registration shall have the right to, in its sole discretion, defer, terminate or withdraw any registration initiated by it under this Section 5.5 whether or not the Shareholder has elected to include any Registrable Securities in such registration. Notwithstanding anything contained herein, in the event that the SEC or applicable federal securities Laws and regulations prohibit the Company from including all of the Registrable Securities requested by the Shareholder to be registered in a registration statement pursuant to this Section 5.5, then the Company shall be obligated to include in such registration statement only such portion of the Registrable Securities as is permitted by the SEC or such federal securities Laws and regulations.
Section 5.6.    Withdrawals.  The Shareholder may withdraw all or any part of the Registrable Securities from a Registration Statement at any time prior to the effective date of such Registration Statement.  If such withdrawal is made primarily as a result of the failure of the Company to comply with any provision of this Agreement, the Company shall be responsible for the payment of all Registration Expenses in connection with such registration and such registration shall not count as a Demand Registration for purposes of Section 5.1. In the case of any other withdrawal, the Shareholder shall pay for the Registration Expenses associated with the withdrawn registration.
Section 5.7.    Registration Procedures. Whenever the Shareholder has made a Request in accordance with Section 5.1 that any Registrable Securities be registered pursuant to this Agreement, the Company shall as expeditiously as reasonably practicable:
(a)    (i) in no event later than 30 days after the receipt by the Company of such a Request, prepare and file with the SEC a Required Registration Statement or Required Shelf Registration Statement, as the case may be, providing for the registration under the Securities Act of the Registrable Securities which the Company has been so requested to register in accordance with the intended methods of distribution thereof specified in such Request, and shall use reasonable best efforts to have such Required Registration Statement or Required Shelf Registration Statement, as the case may be, declared effective by the SEC as soon as practicable thereafter and subject to the Blackout Periods set forth in Section 5.2, to keep such Required Registration Statement or Required Shelf Registration Statement, as the case may be, continuously effective (x) in the case of a Demand Registration, for a period of at least ninety (90) calendar days (or, in the case of an underwritten offering, such period as the underwriters may reasonably require) following 

-17-

US-DOCS\70827213.10

the date on which such Required Registration Statement is declared effective (or such shorter period which shall terminate when all of the Registrable Securities covered by such Required Registration Statement have been sold pursuant thereto) or (y) in the case of a Shelf Registration, until such time as all Registrable Securities covered by such Required Shelf Registration Statement have been sold pursuant thereto, including, in either case, if necessary, by filing with the SEC a post-effective amendment or a supplement to the Required Registration Statement or Required Shelf Registration Statement or the related prospectus or any document incorporated therein by reference or by filing any other required document or otherwise supplementing or amending the Required Registration Statement or Required Shelf Registration Statement, if required by the rules, regulations or instructions applicable to the registration form used by the Company for such Required Registration Statement or Required Shelf Registration Statement or by the Securities Act, the Exchange Act, any state securities or blue sky Laws, or any rules and regulations thereunder, and (ii) before filing such Required Registration Statement or Required Shelf Registration Statement, as the case may be, or any amendments or supplements thereto, provide to the Shareholder and any managing underwriter(s), copies of all documents proposed to be filed or furnished, including documents incorporated by reference, and the Shareholder and the managing underwriter(s) shall have the opportunity to review and comment thereon, and the Company will make such changes and additions thereto as may reasonably be requested by the Shareholder and the managing underwriter(s) prior to such filing, unless the Company reasonably objects to such changes or additions;
(b)    prepare and file with the SEC such amendments and supplements to such Registration Statement and the prospectus used in connection therewith (subject to the review and comment provisions set forth in Section 5.7(a) above) as may be necessary to maintain the effectiveness of such Registration Statement and to comply with the provisions of the Securities Act with respect to the disposition of all securities covered by such Registration Statement for the period set forth in (a) above;
(c)    furnish to the Shareholder and each managing underwriter or other purchaser  such number of copies of such Registration Statement, each amendment and supplement thereto, the prospectus included in such Registration Statement (including each preliminary prospectus) (in each case including all exhibits other than those which are being incorporated into such Registration Statement by reference and that are publicly available) and such other documents as the Shareholder may reasonably request in order to facilitate the disposition of the Registrable Securities owned by the Shareholder;
(d)    use its reasonable best efforts to register or qualify such Registrable Securities under such other securities or blue sky Laws of such jurisdictions in the United States as the Shareholder or any managing underwriter or other purchaser may reasonably requests and do any and all other acts and things which may be reasonably necessary or advisable to enable the Shareholder to consummate the disposition in such jurisdictions of the Registrable Securities owned by the Shareholder; provided that the Company shall not be required to (i) qualify generally to do business in any jurisdiction where it would not 

-18-

US-DOCS\70827213.10

otherwise be required to qualify, (ii) consent to general service of process in any such jurisdiction or (iii) subject itself to taxation in any jurisdiction where it is not so subject;
(e)    in the event of any offering of Registrable Securities pursuant to a Registration Statement, (i) enter into an underwriting agreement or similar agreement, in usual and customary form, with the managing underwriter(s) or other purchaser(s) of Registrable Securities in such offering and use reasonable best efforts to take such other actions as the Shareholder, managing underwriter(s) or other purchaser(s) reasonably request in order to expedite or facilitate the disposition of such Registrable Securities (ii) cause its senior officers to participate in “road shows” and other information meetings organized by the managing underwriter(s) or other purchaser(s) and otherwise reasonably cooperating with the managing underwriter(s) or other purchaser(s) in connection with customary marketing activities (provided however, in no circumstance shall the Company be required to participate in road shows or other information meetings in connection with more than two such offerings in any calendar year) and (iii) cause to be delivered to the Shareholder and the underwriter(s) or other purchaser(s) opinions of counsel to the Company addressed to the underwriter(s) or other purchaser(s), in customary form, covering such matters as are customarily covered by opinions for an underwritten public offering as the underwriter(s) or other purchaser(s) may request;
(f)    notify the Shareholder, at any time when a prospectus relating thereto is required to be delivered under the Securities Act, of the happening of any event as a result of which the prospectus included in such Registration Statement, as then in effect, contains an untrue statement of a material fact or omits any fact necessary to make the statements therein, not misleading, and in such case, subject to Section 5.2, the Company shall promptly prepare a supplement or amendment to such prospectus so that, as thereafter delivered to the holders of such Registrable Securities, such prospectus shall not contain an untrue statement of a material fact or omit to state any fact necessary to make the statements therein, not misleading;
(g)    use its reasonable best efforts to cause all such Registrable Securities which are registered to be listed on each securities exchange on which similar securities issued by the Company are then listed;
(h)    provide and cause to be maintained a transfer agent and registrar for all Registrable Securities covered by such registration statement not later than the effective date of such registration statement;
(h)    enter into such customary agreements and use reasonable best efforts to take all such other actions as the Shareholder and the underwriter(s) or other purchaser(s), if any, reasonably request in order to expedite or facilitate the disposition of such Registrable Securities;
(i)    make available for inspection by the Shareholder and any underwriter or other purchaser participating in any disposition pursuant to such Registration Statement and any attorney, accountant or other agent retained by the Shareholder or any underwriter or 

-19-

US-DOCS\70827213.10

other purchaser, financial and other records, pertinent corporate documents and properties of the Company and its Subsidiaries as shall be reasonably necessary to enable them to exercise their due diligence responsibility, and cause the Company’s officers, directors, employees and independent accountants to supply all other information reasonably requested by the Shareholder or any such underwriter or other purchaser, attorney, accountant or agent in connection with such Registration Statement;
(j)    if such offering of Registrable Securities is made pursuant to a Registration Statement, use reasonable best efforts to obtain “comfort” letters dated the pricing date and the closing date of the offering of the Registrable Securities under the underwriting or other agreement from the Company’s independent public accountants in customary form and covering such matters of the type customarily covered by “comfort” letters in connection with underwritten offerings as the Shareholder, managing underwriter(s) or other purchaser(s) reasonably request;
(k)    use reasonable best efforts to furnish, at the request of the Shareholder on the date such securities are delivered to the underwriter(s) or other purchaser(s) for sale pursuant to such registration or are otherwise sold pursuant thereto, an opinion and a “10b­5” letter, dated such date, of counsel representing the Company for the purposes of such registration, addressed to the underwriter(s) or other purchaser(s) covering such legal and other matters with respect to the registration in respect of which such opinion is being given and such letter is being delivered as the Shareholder, underwriter(s) or other purchaser(s) may reasonably request and are customarily included in such opinions and letters;
(l)    subject to Section 5.2, use reasonable best efforts to prevent the issuance of any stop order, injunction or other order or requirement suspending the effectiveness of the Registration Statement or obtain the withdrawal of any such order if it is issued;
(m)    otherwise use its reasonable best efforts to comply with all applicable rules and regulations of the SEC, and make available to its security holders, as soon as reasonably practicable after the effective date of the Registration Statement, an earnings statement covering the period of at least 12 months beginning with the first day of the Company’s first full calendar quarter after the effective date of the Registration Statement, which earnings statement shall satisfy the provisions of Section 11(a) of the Securities Act and Rule 158 thereunder;
(o)    to the extent permitted by applicable Law, make available to the Shareholder an executed copy of each letter written by or on behalf of the Company to the SEC or the staff of the SEC (or other governmental agency or self-regulatory body or other body having jurisdiction, including any domestic or foreign securities exchange), and any item of correspondence received from the SEC or the staff of the SEC (or other governmental agency or self –regulatory body or other body having jurisdiction, including any domestic or foreign securities exchange), in each case relating to such Registration Statement; respond reasonably and completely to any and all comments received from the SEC or the staff of the SEC, with a view towards causing such Registration Statement or any amendment thereto to be declared effective by the SEC as soon as reasonably practicable and shall file an 

-20-

US-DOCS\70827213.10

acceleration request following the resolution or clearance of all SEC comments or, if applicable, following notification by the SEC that any such registration statement or any amendment thereto will not be subject to review;
(n)    reasonably cooperate with the Shareholder and each underwriter or other purchaser  participating in the disposition of such Registrable Securities and their respective counsel in connection with any filings required to be made with FINRA;
(o)    notify in writing the Shareholder and the underwriter or other purchaser, if any, of the following events as promptly as reasonably practicable:
(i)    the effectiveness of any such Registration Statement;
(ii)    any request by the SEC for amendments or supplements to the Registration Statement or the prospectus or for additional information and when same has been filed and become effective;
(iii)    the issuance by the SEC of any stop order suspending the effectiveness of the Registration Statement or the initiation of any proceedings by any Person for that purpose; 
(iv)    the suspension of the registration of the subject shares of the Registrable Securities in any state jurisdiction; and
(vi)    the receipt by the Company of any notification with respect to the suspension of the qualification of the Registrable Securities for the sale under the securities or blue sky Laws of any jurisdiction or the initiation or threat of any proceeding for such purpose;
(p)    to the extent requested in writing by the lead managing underwriter(s) or other purchaser(s) with respect to an offering of Equity Securities having an aggregate value of at least $50,000,000 pursuant to a Registration Statement, agree, and cause the directors or officers of the Company to agree, to enter into customary agreements restricting the sale or distribution of Equity Securities during the period commencing on the date of the request (which shall be no earlier than fourteen (14) calendar days prior to the expected “pricing” of such offering) and continuing for not more than ninety (90) calendar days after the date of the “final” prospectus (or “final” prospectus supplement if the offering is made pursuant to a Shelf Registration Statement), pursuant to which such  offering shall be made, plus an extension period, as may be proposed by the lead managing underwriter(s) or other purchaser(s) to address FINRA regulations regarding the publishing of research, or such lesser period as is required by the lead managing underwriter(s) or other purchaser(s); and
(q)    use reasonable best efforts to take all other steps reasonably necessary to effect the registration of the Registrable Securities contemplated hereby.

-21-

US-DOCS\70827213.10

If any such registration or comparable statement refers to the Shareholder by name or otherwise as the holder of any securities of the Company and if the Shareholder is or would be reasonably expected to be deemed to be a controlling person of the Company, the Shareholder shall have the right to require (i) the insertion therein of language, in form and substance satisfactory to the Shareholder and presented to the Company in writing, to the effect that the holding by the Shareholder of such securities is not to be construed as a recommendation by the Shareholder of the investment quality of the Company’s securities covered thereby and that such holding does not imply that the Shareholder shall assist in meeting any future financial requirements of the Company or (ii) in the event that such reference to the Shareholder by name or otherwise is not required by the Securities Act or any similar federal statute then in force, the deletion of the reference to the Shareholder. In connection with any Registration Statement in which the Shareholder is participating, the Shareholder shall furnish to the Company in writing such information regarding the Shareholder as the Company may from time to time reasonably request specifically for use in connection with any such Registration Statement or prospectus.
Upon notice by the Company to the Shareholder of any Blackout Period, the Shareholder shall keep the fact of any such notice strictly confidential, and during any Blackout Period, discontinue its offer and disposition of Registrable Securities pursuant to the applicable Registration Statement and the prospectus relating thereto for the duration of the Blackout Period set forth in such notice (or until such Blackout Period shall be earlier terminated in writing by the Company). The Shareholder agrees that upon receipt of any notice from the Company of the happening of any event of the kind described in clauses (f), (q)(ii), (q)(iii), (q)(iv) or (q)(v) above, it shall forthwith discontinue its offer and disposition of Registrable Securities pursuant to the applicable Registration Statement and the prospectus relating thereto until its receipt of the copies of the supplemented or amended prospectus contemplated by clause (o)(ii), or until it is advised in writing by the Company that the use of the applicable prospectus may be resumed, and has received copies of any additional or supplemental filings that are incorporated or deemed to be incorporated by reference in such prospectus; provided that the Company shall use its reasonable best efforts to supplement or amend the applicable Registration Statement and prospectus as promptly as practicable and shall extend the time periods under clause (a) above with respect to the length of time that effectiveness of a Registration Statement must be maintained by the amount of time that the Shareholder is required to discontinue disposition of such Registrable Securities.
Section 5.8.    Registration Expenses. Subject to Section 7.1, (i) all expenses incident to the performance of or compliance with this Article 5, including all registration and filing fees, fees and expenses of compliance with securities or blue sky Laws, printing expenses, messenger and delivery expenses, out-of-pocket expenses and disbursements arising out of or related to any marketing activities undertaken pursuant to Section 5.7(e), the expenses and fees for listing the securities to be registered on each securities exchange on which similar securities issued by the Company are then listed and fees (all such expenses being herein called “Registration Expenses”) and (ii) all other expenses of the Shareholder incident to the registration and sale of Registrable Securities pursuant to this agreement and all fees, costs and expenses of its counsel, accountants, advisers or representatives relating to the registration and sale of Registrable Securities pursuant to this Agreement shall in each case be borne by the Shareholder. The Company shall pay (i) all the Company’s internal expenses (including all salaries and expenses of its officers and employees 

-22-

US-DOCS\70827213.10

performing legal or accounting duties), the expense of any annual audit or quarterly review, the expense of any liability insurance and disbursements of counsel for the Company and all independent certified public accountants retained by the Company and (ii) any underwriter’s discount or commission for the sale of Registrable Securities in underwritten offerings under Sections 5.4 and 5.5 that is 3% or less of the public offering price. 
Section 5.9.    Requested Information. Not less than five (5) Business Days before the expected filing date of each Registration Statement pursuant to this Agreement, the Company shall notify each holder of Registrable Securities who has timely provided the requisite notice hereunder entitling such holder to register Registrable Securities in such Registration Statement of the information, documents and instruments from such holder that the Company or any underwriter or other purchaser reasonably requests in connection with such Registration Statement, including a questionnaire, custody agreement, power of attorney, lock­up letter and underwriting or other agreement, each in customary form reasonably acceptable to such holders (the “Requested Information”). If the Company has not received, on or before the second Business Day before the expected filing date, the Requested Information from such holder, the Company may file the Registration Statement without including Registrable Securities of such holder. The failure to so include in any Registration Statement the Registrable Securities of a holder of Registrable Securities (with regard to that Registration Statement) shall not result in any liability on the part of the Company to such holder.
Section 5.10.    Holdback Agreements. The Shareholder agrees to enter into customary agreements restricting the sale or distribution of Equity Securities (including sales pursuant to Rule 144) to the extent reasonably required in writing by the lead managing underwriters with respect to an applicable underwritten primary offering on behalf of the Company relating to the registration of Equity Securities having an aggregate value of at least $50,000,000 during the period commencing on the date of the request (which shall be no earlier than fourteen (14) calendar days prior to the expected “pricing” of such underwritten offering) and continuing for not more than ninety (90) calendar days after the date of the “final” prospectus (or “final” prospectus supplement if the underwritten offering is made pursuant to a Shelf Registration Statement), pursuant to which such underwritten offering shall be made, plus an extension period, as may be proposed by the lead managing underwriters to address FINRA regulations regarding the publishing of research, or such lesser period as is required by the lead managing underwriters.  The Shareholder shall not be required to enter into a holdback agreement pursuant to this Section 5.10 (a) at any time when the aggregate number of Shares that are Beneficially Owned by the Shareholder and its Group Members, as a group, is less than 10% of the shares of Common Stock issued and outstanding (b) unless the directors and executive officers of the Company are subject to comparable restrictions and (c) unless the Shareholder has had the opportunity to review and provide reasonable comments on any such holdback agreement.  The postponement rights in clause (b) of the first sentence in Section 5.2 and the holdback obligation in this Section 5.10 shall not be applicable to the Shareholder for more than a total of one hundred fifty (150) calendar days during any period of twelve (12) consecutive months.
Section 5.11.    Rule 144 Reporting. With a view to making available to the Shareholder the benefits of certain rules and regulations of the SEC which may permit the sale of 

-23-

US-DOCS\70827213.10

the Registrable Securities to the public without registration, the Company agrees to use its reasonable best efforts to:
(a)    make and keep public information available, as those terms are understood and defined in Rule 144 or any similar or analogous rule promulgated under the Securities Act, at all times after the effective date of the first registration filed by the Company for an offering of its securities to the general public;
(b)    file with the SEC, in a timely manner, all reports and other documents required of the Company under the Exchange Act; and
(c)    so long as the Shareholder owns any Registrable Securities, furnish to the Shareholder promptly upon request (i) a written statement by the Company as to its compliance with the reporting requirements of Rule 144 of the Securities Act and of the Exchange Act, (ii) a copy of the most recent annual or quarterly report of the Company filed with the SEC and (iii) such other reports and documents as the Shareholder may reasonably request in connection with availing itself of any rule or regulation of the SEC allowing it to sell any such securities without registration, in each case to the extent not readily publicly available.
Section 5.12.    Company Indemnification. The Company agrees to indemnify and hold harmless, to the extent permitted by applicable Law, the Shareholder, its Affiliates and each of its and their respective directors, officers, partners, members, employees, advisors, representatives and agents and each Person, if any, who controls the Shareholder (within the meaning of the Securities Act or the Exchange Act) from and against any and all losses, claims, damages, liabilities and expenses whatsoever (including reasonable, documented  expenses of investigation and reasonable, documented attorneys’ fees and expenses) caused by, arising out of or relating to any untrue or alleged untrue statement of material fact contained in any Registration Statement, prospectus or preliminary prospectus or any amendment thereof or supplement thereto covering the resale of any Registrable Securities by or on behalf of the Shareholder or any omission or alleged omission of a material fact required to be stated therein or necessary to make the statements therein not misleading or any violation of the Securities Act or state securities laws or rules thereunder by the Company relating to any action or inaction by the Company in connection with such registration, except insofar as such untrue statement or omission is based on information contained in any affidavit or statement so furnished in writing by the Shareholder expressly stated to be used in connection with such Registration Statement. This indemnity shall be in addition to any liability the Company may otherwise have. Such indemnity shall remain in full force and effect regardless of any investigation made by or on behalf of the Shareholder or any indemnified party and shall survive the transfer of such securities by the Shareholder.
Section 5.13.    Shareholder Indemnification. The Shareholder and any Permitted Transferees jointly and severally agree to indemnify and hold harmless, to the extent permitted by applicable Law, the Company, its Affiliates, its and their respective directors, officers, partners, members and agents and each Person, if any, who controls the Company (within the meaning of the Securities Act or the Exchange Act) from and against any and all losses, claims, damages, liabilities and expenses (including reasonable, documented expenses of investigation and 

-24-

US-DOCS\70827213.10

reasonable, documented  attorneys’ fees and expenses) caused by, arising out of or relating to any untrue or alleged untrue statement of material fact contained in the Registration Statement, prospectus or preliminary prospectus or any amendment thereof or supplement thereto covering the resale of any Registrable Securities by or on behalf of the Shareholder or any omission or alleged omission of a material fact required to be stated therein or necessary to make the statements therein not misleading, but only to the extent that such untrue statement or omission is contained in any information or affidavit so furnished in writing by the Shareholder expressly stated to be used in connection with such Registration Statement.  Notwithstanding the foregoing, the Shareholder shall not be liable for any amounts in excess of the net proceeds received by the Shareholder from sales of Registrable Securities pursuant to the Registration Statement to which the claims relate. This indemnity shall be in addition to any liability the Shareholder may otherwise have. Such indemnity shall remain in full force and effect regardless of any investigation made by or on behalf of the Company or any indemnified party and shall survive the transfer of such securities by the Company.
Section 5.14.    Resolution of Claims. Any Person entitled to indemnification pursuant to this Article 5 shall give prompt written notice to the indemnifying Party of any claim with respect to which it seeks indemnification; provided that the failure so to notify the indemnifying Party shall not relieve the indemnifying Party of any liability that it may have to the indemnified party hereunder except to the extent that the indemnifying Party is materially prejudiced or otherwise forfeits substantive rights or defenses by reason of such failure. If notice of commencement of any such action is given to the indemnifying Party as above provided, the indemnifying Party shall be entitled to participate in and, to the extent it may wish, jointly with any other indemnifying Party similarly notified, to assume the defense of such action at its own expense, with counsel chosen by it and reasonably satisfactory to such indemnified party. The indemnified party shall have the right to employ separate counsel in any such action and participate in the defense thereof, but the fees and expenses of such counsel shall be paid by the indemnified party unless (a) the indemnifying Party agrees to pay the same, (b) the indemnifying Party fails to assume the defense of such action with counsel reasonably satisfactory to the indemnified party within a reasonable amount of time after receipt of notice of such claim from the Indemnified Parry or (c) the named parties to any such action (including any impleaded parties) include both the indemnifying Party and the indemnified party and such parties have been advised by such counsel that either (i) representation of such indemnified party and the indemnifying Party by the same counsel would be inappropriate under applicable standards of professional conduct or (ii) it is reasonably foreseeable that there will be one or more material legal defenses available to the indemnified party which are different from or additional to those available to the indemnifying Party. In any of such cases, the indemnified party shall have the right to participate in the defense of such action with its own counsel, the reasonable, documented out-of-pocket fees and expenses of which shall be paid by the indemnifying Party, it being understood, however, that the indemnifying Party shall not be liable for the fees and expenses of more than one separate firm of attorneys (in addition to any local counsel) for all indemnified parties. No indemnifying Party shall be liable for any settlement entered into without its written consent (such consent not to be unreasonably withheld, conditioned or delayed). No indemnifying Party shall, without the consent of such indemnified party (such consent not to be unreasonably withheld, conditioned or delayed), effect any settlement of any pending or threatened proceeding in respect of which such indemnified party is a party and indemnity has been sought hereunder by such indemnified party, unless such settlement (x) includes an unconditional release of such 

-25-

US-DOCS\70827213.10

indemnified party from all liability for claims that are the subject matter of such proceeding and (y) does not include an omission of fault, culpability or failure to act by or on behalf of any indemnified party.
Section 5.15.    Contribution. If the indemnification provided for in Section 5.12 or Section 5.13 is held by a court of competent jurisdiction to be unavailable to an indemnified party with respect to any losses, claims, damages or liabilities referred to herein, the indemnifying Party, in lieu of indemnifying such indemnified party thereunder, shall to the extent permitted by applicable Law contribute to the amount paid or payable by such indemnified party as a result of such loss, claim, damage or liability in such proportion as is appropriate to reflect the relative fault of the indemnifying Party on the one hand and of the indemnified party on the other in connection with such loss, claim, damage or liability, as well as any other relevant equitable considerations. The relative fault of the indemnifying Party and of the indemnified party shall be determined by a court of Law by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission to state a material fact relates to information supplied by the indemnifying Party or by the indemnified party and the parties’ relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission. The amount paid or payable by a party as a result of any loss, claim, damage or liability referred to above shall be deemed to include, subject to the limitations set forth in this Section 5.15, any legal or other fees, charges or expenses reasonably incurred by such party in connection with any investigation or proceeding. The Parties agree that it would not be just and equitable if contribution pursuant to this Section 5.15 were determined by pro rata allocation or by any other method of allocation which does not take account of the equitable considerations referred to in this Section 5.15. No Person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) shall be entitled to contribution from any Person who was not guilty of such fraudulent misrepresentation.
Section 5.16.    Company Facilitation of Sale. If any Registrable Securities are certificated and bear any restrictive legend, or are held in non-certificated book-entry form and are subject to any stop transfer or similar instruction or restriction, the Company shall upon the request of the holder of such Registrable Securities, as applicable, promptly cause such legends to be removed and new certificates without any restrictive legends to be issued or cause such stop transfer or similar instructions or restrictions to be promptly terminated and removed if (a) such Registrable Securities have been resold pursuant to an effective Registration Statement or (b) the holder of such Registrable Securities provides the Company and/or transfer agent, as applicable, with reasonable assurance that such Registrable Securities can be sold, assigned or transferred pursuant to Rule 144 or otherwise without registration and without any restriction whatsoever under the applicable requirements of the Securities Act, including, if requested by the Company, an opinion of outside legal counsel, reasonably acceptable to the Company and/or transfer agent, as applicable, to such effect. 
Section 5.17.    Transfers.  To the extent that any Registrable Securities are Transferred, the obligations of the Company shall not be expanded in any respect and, the registration rights provided for in this Article 5, to the extent assigned, shall be shared by all holders of Registrable Securities and all such persons shall be jointly and severally liable for any obligations.
ARTICLE 6
Board of Directors
Section 6.1.    Composition. Prior to the execution of this Agreement, the Company has taken all actions necessary to increase the number of directors that shall constitute the entire Board of Directors to nine (9) directors and, effective as of the date hereof, has appointed to the Board of Directors Doug Giordano as a director to serve until his successor is elected and qualified or his resignation or removal in accordance with the bylaws of the Company.  For so long as the Shareholder maintains the right to designate one director pursuant to Section 6.2, the Company shall not support any increase in the number of directors of more than nine (9) total directors without the Shareholder’s prior written consent. 
Section 6.2.    Designation of Director.  From the date hereof for so long as Shareholder has Beneficial Ownership at least 10% of the total outstanding shares of Common Stock at such time, the Shareholder shall have the right to designate one (1) individual for election to the Board of Directors, the identity of such director designee to be at the discretion of the Shareholder so long as any such director designee is not restricted from serving on the board of directors of a U.S. public company and shall satisfy the corporate governance guidelines of the Company and NASDAQ.  
Section 6.3.    Election of Director.  For so long as the Shareholder is entitled to designate an individual for election to the Board of Directors pursuant to Section 6.2, the Company shall nominate and take all action within its power to cause all nominees designated pursuant to Section 6.2 to be included in the slate of nominees recommended by the Board of Directors to the Company's stockholders for election as directors at each annual or special meeting of the stockholders of the Company at which directors are to be elected to the Board of Directors (and/or in connection with any election by written consent) and the Company shall use all reasonable best efforts to cause the election of each such nominee, including recommending and soliciting proxies in favor of the election of such nominees. 
Section 6.4.    Replacement of Director. In the event that a vacancy is created at any time by the death, disability, retirement, resignation or removal (with or without cause) of the director nominated pursuant to Section 6.2 or 6.3, or in the event of the failure of any such nominee to be elected, the Shareholder shall have the right to designate a replacement to fill such vacancy, provided that any such nominee shall (i) be an officer of the Shareholder and hold a title of Senior Vice President or above, (ii) not be restricted from serving on the board of directors of a U.S. public company and (iii) satisfy the corporate governance guidelines of the Company and NASDAQ. The Company shall take all action within its power to cause such vacancy to be filled by the replacement so designated, and the Board of Directors shall promptly elect such designee to the Board of Directors.  Upon the written request of the Shareholder, the Company shall take all action within its power to submit to a vote of stockholders of the Company.
Section 6.5.    Indemnification, Fees, Expense Reimbursement and Insurance.  Any director designated or nominated by the Shareholder that serves on the Board of Directors shall be entitled to all benefits and rights under any indemnification, exculpation and reimbursement 

-26-

US-DOCS\70827213.10

agreement, policy and provision of any organizational document (including as to advancement or reimbursement of expenses), as well as any director and officer insurance policy maintained by the Company, in each case to the fullest extent made available to any other director of the Board of Directors.  Without limiting the foregoing, (i) the benefits and rights referenced in the previous sentence shall not be amended, repealed or otherwise modified in any manner that would adversely affect the rights thereunder of any director designated or nominated by the Shareholder without the Shareholder’s prior written consent and (ii) the Company shall at all times maintain in full force and effect a policy or policies of director and officer liability insurance, issued by insurers of recognized responsibility, insuring against such losses and risks, and in such amounts, as are at least as favorable as are maintained by the Company as of the date hereof.  Notwithstanding anything to the contrary in the Company's certificate of incorporation or bylaws or in this Section 6.7, and without limiting any of the rights set forth therein, the Company shall indemnify and hold harmless any director designated or nominated by the Shareholder that serves on the Board of Directors to the fullest extent permitted by applicable law with respect to any losses arising from or related to the fact that such director is or was a director of the Company, or is or was serving at the request of the Company as a director, officer, employee, or agent of the Company or another corporation or of a partnership, joint venture, trust or other enterprise, including service with respect to employee benefit plans, or by reason of anything done or not done by such director in any such capacity.  The Company hereby agrees to enter into a customary indemnification agreement with the director designated or nominated by the Shareholder as soon as reasonably practicable after the date hereof. No director designated or nominated by the Shareholder that serves on the Board of Directors shall be entitled to any compensation by the Company for service as a director, and the Shareholder shall cause any director designated or nominated by the Shareholder that serves on the Board of Directors to waive any right to compensation, including any cash retainer payments and equity awards payable to members of the Board of Directors.  
Section 6.6.    No Impairment. The Company shall not take any action to cause the amendment of its certificate of incorporation or bylaws such that Article VI would not be given effect; provided, that, for the avoidance of doubt, the foregoing shall not prohibit any increase or decrease in the size of the Board of Directors subject to the rights of the Shareholder upon any increase set forth in Section 6.1 above.  
Section 6.7.    Compliance Matters.  The Company, its Subsidiaries and Affiliates shall use its commercially reasonable efforts to (i) comply in all material respects with all Laws applicable to the Company, its business or operations, including (A) Anti-Corruption Laws in any jurisdiction where the Company (or, if applicable, any of its Subsidiaries) is organized, holds assets or operates, or in which its products are sold and (B) all Laws governing interactions with government officials and Healthcare Professionals in any of the jurisdictions described in clause (i), (ii) maintain books, records, and accounts that, in all material respects, accurately and fairly reflect the transactions and dispositions of their respective assets, (iii) maintain at all times a code of conduct, an anti-corruption policy and procedure, and appropriate systems of internal controls that provide reasonable assurances that the Company and each of its Subsidiaries and Affiliates will comply with Anti-Corruption Laws that are appropriate in light of the nature and type of the activities engaged in by the Company, its Subsidiaries and Affiliates, and (iv)  monitor their respective operations with the purpose of ensuring the effectiveness of the Company’s anti-corruption policies, 

-27-

US-DOCS\70827213.10

procedures, systems and controls and, when appropriate, undertake reasonable enhancements as their business activities expand.
ARTICLE 7
Miscellaneous
Section 7.1.    Fees and Expenses. Except as otherwise provided in this Agreement (including in Section 5.8), each Party shall pay its own direct and indirect expenses incurred by it in connection with the preparation and negotiation of this Agreement and the consummation of the transactions contemplated by this Agreement, including all fees and expenses of its advisors and representatives.
Section 7.2.    Term. Notwithstanding anything contained herein to the contrary, this Agreement shall terminate, and all rights and obligations hereunder shall cease, upon such time as there are no Registrable Securities, except for the provisions of Sections 5.8, 5.12, 5.13, 5.14, 5.15 and this Article 7, which shall survive such termination.
Section 7.3.    Notices. All notices and other communications in connection with this Agreement shall be in writing and shall be given or made (and shall be deemed to have been duly given or made upon receipt) by delivery in person, by overnight courier service, by facsimile with receipt confirmed (followed by delivery of an original via overnight courier service) or by registered or certified mail (postage prepaid, return receipt requested) to the respective Parties at the following addresses:
If to the Company, to:
 
ICU Medical, Inc.
951 Calle Amanecer
San Clemente, CA 92673
Attn:    General Counsel

with a copy (which shall not constitute notice) to: 

Latham & Watkins LLP
650 Town Center Drive, 20th Floor
Costa Mesa, CA 92626
Attn:    Charles Ruck; Thomas Christopher 

If to the Shareholder, to:

 
            Pfizer Inc. 
235 East 42nd Street 
New York, NY 10017
Attn: 

-28-

US-DOCS\70827213.10

with a copy (which shall not constitute notice) to: 

Pfizer Inc. 
235 East 42nd Street 
27th Floor
New York, NY 10017
Attn: Senior Vice President and Deputy General Counsel, Business Transactions Group 

Skadden Arps Slate Meagher & Flom LLP    
4 Times Square 
New York, NY 10016
Attn:  Paul T. Schnell 
           Kenneth Wolff 

Any Party may, by delivery of written notice to the other Parties, change the address to which such notices and other communications are to be given in connection with this Agreement.
Section 7.4.    Counterparts; Entire Agreement; Corporate Power; Facsimile Signatures.  This Agreement may be executed in one or more counterparts, all of which shall be considered one and the same agreement. This Agreement and the Schedules hereto contain the entire agreement between the Parties with respect to the subject matter hereof, supersede all previous agreements, negotiations, discussions, writings, understandings, commitments and conversations with respect to such subject matter and there are no agreements or understandings between the Parties other than those set forth or referred to herein or therein.  Each Party acknowledges that it and the other Parties may execute this Agreement by manual, stamp, mechanical or electronic signature, and that delivery of an executed counterpart of a signature page to this Agreement (whether executed by manual, stamp, mechanical or electronic signature) by facsimile or by email in portable document format (PDF) shall be effective as delivery of such executed counterpart of this Agreement.  Each Party expressly adopts and confirms a stamp, mechanical or electronic signature (regardless of whether delivered in person, by mail, by courier, by facsimile or by email in portable document format (PDF)) made in its respective name as if it were a manual signature delivered in person, agrees that it shall not assert that any such signature or delivery is not adequate to bind such Party to the same extent as if it were signed manually and delivered in person and agrees that, at the reasonable request of the other Party at any time, it shall as promptly as reasonably practicable cause this Agreement to be manually executed (any such execution to be as of the date of the initial date thereof) and delivered in person, by mail or by courier.
Section 7.5.    Amendments and Waivers. No provision of this Agreement may be waived, modified, supplemented or amended except in a written instrument signed, in the case of an amendment, by the Company and the Shareholder or, in the case of a waiver, by the Party against whom enforcement of any such waived provision is sought. No waiver of any default with respect to any provision, condition or requirement of this Agreement shall be deemed to be 

-29-

US-DOCS\70827213.10

a continuing waiver in the future or a waiver of any subsequent default or a waiver of any other provision, condition or requirement hereof, nor shall any delay or omission of any Party to exercise any right hereunder in any manner impair the exercise of any such right.
Section 7.6.    Successors and Assigns.  Subject to clauses (a) and (b) below, this Agreement shall be binding upon the Parties and their respective successors and assigns and shall inure to the benefit of the Parties and their respective successors and permitted assigns.
(a)    The Company may not assign or delegate this Agreement or any rights or obligations hereunder without the prior written consent of the Shareholder; provided that no such consent shall be required for any assignment by the Company of its rights or obligations hereunder in connection with a merger, consolidation, combination, reorganization or similar transaction or the transfer, sale, lease, conveyance or disposition of all or substantially all of its assets.
(b)    The Shareholder may not assign or delegate this Agreement or any rights or obligations hereunder without the prior written consent of the Company; provided that no such consent shall be required for (i) subject to Section 7.6(d), any assignment by the Shareholder of its rights or obligations hereunder (other than in Section 6) in connection with a merger, consolidation, combination, reorganization or similar transaction in or to which the Shareholder is a constituent Person or the transfer, sale, lease, conveyance or disposition of all or substantially all of the Shareholder’s assets, if such assignee agrees in writing to be bound by the terms of this Agreement or (ii) (x) the assignment or delegation by the Shareholder of any of its rights or obligations under this Agreement to a Permitted Transferee or (y) in any other Transfer made in accordance with Section 2.1 of at least 5% of the then issued and outstanding shares of Common Stock of the Company, if, in the case of (ii)(x) and (ii)(y) above, such  transferee agrees in writing to be bound by the terms of this Agreement (other than Section 6 in the case of (ii)(y) above) and together with the Shareholder and any prior transferees shall be deemed the Shareholder; provided further that no such assignment or delegation shall relieve the Shareholder of its obligations under this Agreement. For the avoidance of doubt, the Shareholder may not assign or delegate any of its rights or obligations under Section 6 without the prior written consent of the Company. 
(c)    Except as provided in Section 7.6(d), the covenants and agreements of the Shareholder set forth in Articles 2, 3 and 4 shall not be binding upon or restrict any transferee of Shares other than Permitted Transferees in accordance with Section 2.1(a)(iii) or any transferee of Shares pursuant to a Transfer in connection with which the Shareholder’s rights under this Agreement are assigned to the transferee pursuant to Section 7.6(b)(i), and no transferee of Shares other than such Permitted Transferees or a transfer of the Shareholder’s rights pursuant to Section 7.6(b) shall have any rights under this Agreement.
(d)    The Shareholder will not enter into any transaction pursuant to which any Person would become its ultimate parent entity (such that the Shareholder is a direct or indirect Subsidiary of another Person or all or substantially all of the Shareholder’s equity securities or assets have been acquired by another Person) without causing such Person to assume all of the Shareholder’s obligations under this Agreement effective as of the consummation of such transaction.

-30-

US-DOCS\70827213.10

Section 7.7.    Non-Affiliation. From and after the date of this Agreement, the Company shall not and shall not cause, direct or permit any of its Subsidiaries or Group Members to (a) identify the Shareholder or any of its Affiliates (each, a “Shareholder Party” and collectively, the “Shareholder Parties”) or otherwise hold any Shareholder Party out to be an Affiliate of the Company or any of its Subsidiaries, except to the extent that such identification is required by applicable Law, by virtue of the Shareholder’s Beneficial Ownership of all or a portion of the Shares or other Equity Securities, and in such case only to the extent so required by Law, or (b) make, enter into, modify or amend any Contract, other than a Contract executed and delivered by any Shareholder Party, that subjects any Shareholder Party or any of its assets or properties (other than the Shares or other Equity Securities held by the Shareholder), tangible or intangible, to any lien, encumbrance, claim, restriction or similar obligation or grants or allows on or with respect to any such assets or properties any right of use, exploitation, access or discovery to or in favor of any Person.
Section 7.8.    Acknowledgment of Securities Laws. Each Party is aware, and shall advise its Representatives who are informed of the matters that are the subject of this Agreement, of the restrictions imposed by the securities laws of the United States on the purchase or sale of securities by any Person who has received material, nonpublic information from the issuer of such securities and on the communication of such information to any other person when it is reasonably foreseeable that such other person is likely to purchase or sell such securities in reliance upon such information.
Section 7.9.    No Third Party Beneficiaries. Except as expressly provided in Section 5.13, 5.14, 5.15 and 5.16, this Agreement is intended for the benefit of the Parties and their respective successors and permitted assigns.
Section 7.10.    Severability. In the event that any one or more of the terms or provisions of this Agreement or the application thereof to any Person or circumstance is determined by a court of competent jurisdiction to be invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability shall not affect any other term or provision of this Agreement, or the application of such term or provision to Persons or circumstances or in jurisdictions other than those as to which it has been determined to be invalid, illegal or unenforceable, and the Parties shall use their commercially reasonable efforts to substitute one or more valid, legal and enforceable terms or provisions into this Agreement which, insofar as practicable, implement the purposes and intent of the Parties. Any term or provision of this Agreement held invalid or unenforceable only in part, degree or within certain jurisdictions shall remain in full force and effect to the extent not held invalid or unenforceable to the extent consistent with the intent of the Parties as reflected by this Agreement. To the extent permitted by applicable Law, each Party waives any term or provision of Law which renders any term or provision of this Agreement to be invalid, illegal or unenforceable in any respect.
Section 7.11.    Business Days. If the last or appointed day for the taking of any action or the expiration of any right required or granted in this Agreement is not a Business Day (including where such period of time is measured in calendar days), then such action may be taken or such right may be exercised on the next succeeding Business Day.
Section 7.12.    Governing Law and Venue: Waiver of Jury Trial. 

-31-

US-DOCS\70827213.10

(a)    THIS AGREEMENT SHALL BE DEEMED TO BE MADE IN AND IN ALL RESPECTS SHALL BE INTERPRETED, CONSTRUED AND GOVERNED BY AND IN ACCORDANCE WITH THE SUBSTANTIVE AND PROCEDURAL LAWS OF THE STATE OF DELAWARE, WITHOUT REGARD TO ITS RULES OF CONFLICTS OF LAW. The Parties irrevocably submit to the exclusive jurisdiction of the Court of Chancery of the State of Delaware, or, to the extent the court of Chancery does not have subject matter jurisdiction, the federal courts of the United States of America for the District of Delaware with respect to all matters arising out of or relating to this Agreement and the interpretation and enforcement of the provisions of this Agreement, and of the documents referred to in this Agreement, and in respect of the transactions contemplated by this Agreement, and waive, and agree not to assert, as a defense in any action, suit or proceeding for the interpretation or enforcement hereof or of any such document, that it is not subject thereto or that such action, suit or proceeding may not be brought or is not maintainable in such courts or that the venue thereof may not be appropriate or that this Agreement or any such document may not be enforced in or by such courts, and the Parties agree that all claims with respect to such action or proceeding shall be heard and determined exclusively in such Court of Chancery or federal court. The Parties agree that a final judgment in any such any action, suit or proceeding shall be conclusive and may be enforced in other jurisdictions by suit on the judgment or in any other manner provided by Law. The Parties consent to and grant any such court jurisdiction over the person of such Parties solely for such purpose and over the subject matter of such dispute and agree that mailing of process or other papers in connection with any such action or proceeding in the manner provided in Section 6.3 or in such other manner as may be permitted by Law shall be valid and sufficient service.
(b)    EACH PARTY IRREVOCABLY AND UNCONDITIONALLY WAIVES ANY RIGHT SUCH PARTY MAY HAVE TO A TRIAL BY JURY WITH RESPECT TO ANY LITIGATION DIRECTLY OR INDIRECTLY ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT. EACH PARTY ACKNOWLEDGES AND AGREES THAT NO REPRESENTATIVE, AGENT OR ATTORNEY OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER. EACH PARTY UNDERSTANDS AND HAS CONSIDERED THE IMPLICATIONS OF THIS WAIVER. EACH PARTY MAKES THIS WAIVER VOLUNTARILY AND EACH PARTY HAS BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS IN THIS SECTION 6.12(b).
Section 7.13.    Enforcement. The Parties acknowledge and agree that irreparable damage would occur in the event that any provision of this Agreement was not performed in accordance with its specific terms or was otherwise breached, and that monetary damages, even if available, would not be an adequate remedy therefor. It is accordingly agreed that the Parties shall be entitled to an injunction or injunctions to prevent breaches of this Agreement and to enforce specifically the performance of the terms and provisions hereof in any court referred to in Section 7.12, without proof of actual damages (and each Party hereby waives any requirement for the securing or posting of any bond in connection with such remedy), this being in addition to any other remedy to which they are entitled at Law or in equity. The Parties further agree not to assert that a 

-32-

US-DOCS\70827213.10

remedy of specific enforcement is unenforceable, invalid, contrary to Law or inequitable for any reason, nor to assert that a remedy of monetary damages would provide an adequate remedy for such breach.
[Signature pages follow]

-33-

US-DOCS\70827213.10

IN WITNESS WHEREOF, the Company and the Shareholder have caused this Agreement to be signed by their respective officers thereunto duly authorized, all as of the date first above written.
	
				
	 
	 
	 
	 

	 
	[  ̃ ]

	 
	 
	 
	 

	 
	 
	 
	 

	 
	By:
	 

	 
	 
	Name:
	 

	 
	 
	Title:
	 

	 
	 
	 
	 

	 
	 
	 
	 

	 
	[  ̃ ]

	 
	 
	 
	 

	 
	 
	 
	 

	 
	By:
	 

	 
	 
	Name:
	 

	 
	 
	Title:
	 

	 
	 
	 
	 

	 
	 
	 
	 

	 
	 
	 
	 

	 
	 
	 
	 

SCHEDULE I

COMPANY COMPETITORS

•         Becton Dickinson
•         Baxter
•         Braun
•         Smiths Medical
•         Fresenius SE
•         Terumo 
•         3M
•         Cardinal Health
•         Owens & Minor
•         McKesson
•         Medline
•         Piza
 

SCHEDULE II

OTHER REGISTRABLE SECURITIES

[TO COME AT SIGNING]SETTLEMENT
AND LICENSE AGREEMENT

 

This
SETTLEMENT AND LICENSE AGREEMENT (this “Agreement”)
is made and entered into as of the date of the last signature required by this Agreement (the “Effective
Date”) by and between Enzo Life Sciences, Inc., a
corporation organized and existing under the laws of the State of New York, having offices at 10 Executive Boulevard, Farmingdale,
NY 11735 (“Enzo”) and Illumina,
Inc., a corporation organized and existing under the laws of the State of Delaware, having offices at 5200 Illumina
Way, San Diego, CA 92122 (“Illumina”).
Enzo and Illumina are individually referred to herein as a “Party,”
and collectively as the “Parties.”

 

WITNESSETH

 

WHEREAS, Enzo has alleged that Illumina
infringes U.S. Patent No. 7,064,197 (“the
‘197 Patent”) in an action styled Enzo
Life Sciences, Inc. v. Illumina,
Inc., No. 1:12-cv-435-LPS, pending in the United States District Court for the District of Delaware (the “Litigation”);
and

 

WHEREAS,
Enzo represents and warrants that it is the owner of, with all substantive rights in and to, the Licensed Enzo Patent Rights (as
defined below) and has the exclusive right to license, collect royalties, collect past, present, or future damages, and to enforce
with legal standing, the Licensed Enzo Patent Rights; and

 

WHEREAS,
Illumina denies all liability in the Litigation; and

 

WHEREAS,
Illumina has alleged that it does not infringe the ‘197 Patent, and further, that the ‘197 Patent is invalid and unenforceable;
and

 

WHEREAS,
Enzo disputes Illumina’s allegations of invalidity, unenforceability, and non-infringement; and

 

WHEREAS,
without admitting infringement or liability and in part to avoid the necessity, expense, inconvenience, and uncertainty of additional
or continued litigation, the Parties now desire to settle the Litigation and to provide and receive certain releases, licenses
and covenants not to sue, all on the terms and conditions set forth herein; and

 

WHEREAS,
this Agreement reflects a settlement and compromise between the Parties under Federal Rule of Evidence 408 with respect to Enzo’s
claims and Illumina’s defenses in the Litigation, including without limitation on the disputed issues of patent validity,
enforceability, and infringement;

 

NOW, THEREFORE,
in consideration of the above recitals and the mutual covenants hereinafter contained and other good and valuable consideration
the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows:

 

	

REVIEWED
BY LEGAL

Initials: RHS

Date: 6/29/16

ILLUMINA

	 

 

	1	SUBJECT TO FRE 408

    	 

    	

    

SECTION
1: DEFINITIONS

 

As used
in this Agreement, the following terms shall have the following meanings:

 

“Affiliate”
means, with respect to a Party and subject to Sections 2.1 and 2.7, any Person that, on or after the Effective Date, is directly
or indirectly controlling, controlled by, or under common control with, such Party. For purposes of this Agreement, “control”
means the ability to control the direction of the management and operations of the subject Person, whether through ownership, contract
or otherwise. Control will be presumed where a Party has direct or indirect ownership of (or the contractual right to direct the
voting of) 50% or more of the voting shares, equity or other interests of the Person. Notwithstanding anything to the contrary
herein, the following Persons are not, and cannot be considered, Affiliates of Illumina for the purposes of this Agreement so long
as any patent infringement litigation or royalty obligation existing as of the Effective Date concerning the Licensed Enzo Patent
Rights remains pending between Enzo and that Person (or any Affiliate of that Person): Abbott Laboratories; Abbott Molecular, Inc.;
Becton, Dickinson and Company; Becton, Dickinson Diagnostics, Inc.; Geneohm Sciences, Inc. (now part of Becton Dickinson); Gen-Probe,
Inc. (now part of Hologic, Inc.); Hologic, Inc.; Roche Molecular Systems, Inc. (part of Hoffmann-La Roche AG); Roche Diagnostics
Corporation (part of Hoffmann-La Roche AG); Roche Diagnostics Operations Inc. (part of Hoffmann-La Roche AG); and Roche Nimblegen,
Inc. (part of Hoffmann-La Roche AG); or any Third Party that is directly or indirectly controlling, controlled by, or under common
control with any of the foregoing Persons.

 

“AmpiProbe
Technology” means nucleic acid amplification detection assays, such as quantitative polymerase chain reaction
(qPCR) assays marketed and sold by Enzo under the tradename AmpiProbe, and nucleic acid probes used therein, in which a first
amplification primer includes a first label/dye/moiety that interacts via FRET (Förster/fluorescence resonance energy transfer)
with a second label/dye/moiety attached to a second amplification primer, or to nucleic acid monomers, upon formation of a nucleic
acid amplification product incorporating the first primer and the second primer, or the first primer and the labeled nucleic acid
monomers.

 

“Cellular
Analysis Technology” means cell flow cytometry assays, cell microscopy assays and cell-on-microplate assays that
utilize nucleic acid hybridization probes. For the avoidance of doubt, Cellular Analysis Technology does not involve sequencing
of nucleic acids.

 

“Claims”
means all claims, counterclaims, counter-counterclaims, actions, causes of action, suits, demands, judgments, debts, expenses (including
attorneys’ fees and costs), losses, liabilities, and obligations of any kind and of whatever nature or character, worldwide,
whether known or unknown, asserted or unasserted, suspected or unsuspected, matured or unmatured, or whether accrued, actual, contingent,
latent or otherwise, made, asserted, or brought for any purpose, including without limitation for the purpose of recovering any
damages or for the purpose of obtaining equitable relief or any other relief or remedy of any kind.

 

“Covered
Third Party Products” means (i) any Third Party products and services, product lines, devices, systems, assays,
components, subassemblies, kits, hardware, software, or any combination of the foregoing provided to Illumina or its Affiliates
for the benefit of Illumina or

 

	

REVIEWED
BY LEGAL

Initials: RHS

Date: 6/29/16

ILLUMINA

	 

 

	2	SUBJECT TO FRE 408

    	 

    	

    

its Affiliates
and constituting a component or element of, or that are used in combination with, any Illumina Product, but only to the extent
of such use as incorporated into such Illumina Product, or (ii) any Third Party products and services that include as a component
or element thereof any Illumina Product, but only to the extent that such Third Party products and services include as a component
or element thereof such Illumina Product.

 

“Illumina
Products” means any past, current and future products and services, product lines, devices, systems, assays, components,
subassemblies, kits, hardware, software, or any combination of the foregoing which are made, used, sold, offered for sale, distributed,
imported, or otherwise commercialized by or for Illumina or its Affiliates, and Natural Evolutions thereof, that, but for the license
granted in this Agreement, infringe (actually or allegedly) a Valid Claim of the Licensed Enzo Patent Rights. For the avoidance
of doubt, all accused products, manufactured articles, services, processes, systems, or methods that are the subject of the Litigation
are included in and constitute Illumina Products.

 

“Licensed
Enzo Patent Rights” means (i) the ‘197 Patent; (ii) any patents and patent applications
claiming priority to or through, or sharing a common priority claim with the ‘197 Patent; and (iii) any foreign
counterparts, re-issues, re-examinations, renewals, substitutes, claim amendments made in post-grant proceedings including
IPR and PGR proceedings, extensions, continuations, continuations-in-part, continuing prosecution applications, divisionals,
and national phase filings of any patents and patent applications covered in subparts (i) and (ii), whether any of the
foregoing are filed before, on or after the Effective Date, in all countries of the world.

 

“Liquid
Phase Nucleic Acid Amplification Detection Technology” means (i) AmpiProbe Technology and (ii) assays that directly
compete (now or in the future) therewith (such as, without limitation, TaqMan, Molecular Beacons, Invader, RealTime PCR, Hybridization
Protection Assay (HPA), or Scorpion technologies), where detection of the targets or analytes of interest occurs in liquid phase
(e.g., where the analyte or target is not attached to or otherwise associated with a solid support). For the avoidance of doubt,
Liquid Phase Nucleic Acid Amplification Detection Technologies do not include sample preparation or library preparation components,
products or services that do not involve liquid phase detection of nucleic acid amplification.

 

“Natural
Evolutions” means modifications, revisions, additions, enhancements, updates, upgrades, changes or similar alterations
to an original product or service, in which the original product or service retains its essential character or remains identifiable.

 

“NIPT”
means in vitro cell-free nucleic acid-based non-invasive prenatal testing (including, without limitation, testing by massively
parallel sequencing or digital PCR) of a biological sample (including but not limited to plasma, serum, whole blood, and urine)
obtained from a pregnant woman.

 

“Person”
means an individual, trust, corporation, partnership, joint venture, limited liability company, association, unincorporated organization,
or other legal entity.

 

	

REVIEWED
BY LEGAL

Initials: RHS

Date: 6/29/16

ILLUMINA

	 

 

	3	SUBJECT TO FRE 408

    	 

    	

    

“Related
Persons” means, with respect to any Person, collectively, (a) all directors, officers, managers and employees
of such Person (to the extent acting in in such capacity); (b) all representatives, agents, attorneys and insurers of such Person
(to the extent acting in such capacity); (c) with respect to Illumina or its Affiliates only, (i) all Persons engaged in the design,
manufacture or supply of parts or components for Illumina Products on behalf of Illumina or its Affiliates (to the extent acting
in such capacity), and (ii) all direct or indirect customers, users, dealers, distributors and other purchasers of Illumina Products
from Illumina or its Affiliates (to the extent acting in such capacity); and (d) all predecessors-in-interest of such Person (in
such capacity).

 

“Third
Party” means any Person or entity other than the Parties to this Agreement and their Affiliates.

 

“Valid Claim” means
a claim of an issued patent that has not expired or been finally held invalid or unenforceable by a court or administrative body
of competent jurisdiction from which no appeal can be or is taken.

 

SECTION
2: LICENSE, RELEASES, AND COVENANTS

 

2.1 License.
Subject to Illumina’s timely payment of the Payment under Section 3.1, Enzo hereby grants (and agrees to grant) to Illumina
and its Affiliates a perpetual, irrevocable, fully paid-up, non-exclusive, non-transferable (except as set forth in Section 5),
worldwide license under the Licensed Enzo Patent Rights to, directly or indirectly, make, have made, use, import, export, market,
distribute, sell, offer for sale, and otherwise commercialize the Illumina Products and Covered Third Party Products. For the avoidance
of doubt, payment of the Payment will satisfy any and all past, present, and future obligations potentially owing to Enzo based
upon or arising in connection with commercialization of any Illumina Products or other potential infringement (direct, induced,
indirect, contributory, or otherwise) of the Licensed Enzo Patent Rights by or for Illumina and its Affiliates, and no additional
payments will be owed to Enzo or its Affiliates in connection with the license granted in this Section 2.1.

 

Illumina
and its Affiliates shall not have the right to sublicense or otherwise grant, in whole or in part, sublicenses under the Licensed
Enzo Patent Rights. The license granted herein shall not extend to cover any products of a Third Party that acquires or is acquired
by Illumina or its Affiliates on or after the Effective Date (whether by merger, consolidation, share acquisition, or acquisition
of all or substantially all assets or otherwise), including without limitation products made, used, imported, exported, distributed,
sold, offered for sale, developed, advertised, and practiced by such Third Party before the date of such acquisition. The license
granted herein shall not include any rights to the Licensed Enzo Patent Rights other than those expressly provided by this section.
No license or immunity is granted under this Agreement by Enzo, either directly or by implication, estoppel, or otherwise, to any
Person acquiring Illumina Products for the modification or combination by such Person of Illumina Products with other items other
than in the ordinary manner in the ordinary course of use of Illumina Products, or as specified in Sections 2.2 and 2.3, or as
otherwise permitted by the law of patent exhaustion.

 

2.2 Enzo
Release of Illumina. Subject to the terms and conditions hereof, including Illumina’s timely payment of the Payment
under Section 3.1, Enzo, on behalf of itself, its Affiliates, and

 

	

REVIEWED
BY LEGAL

Initials: RHS

Date: 6/29/16

ILLUMINA

	 

 

	4	SUBJECT TO FRE 408

    	 

    	

    

their respective
legal successors and assigns (collectively, “Enzo
Releasing Parties”) hereby releases, acquits and absolutely and forever discharges Illumina and its Affiliates
(collectively, “Illumina Released Persons”)
of and from any and all Claims, whether now known or unknown, related to the alleged infringement of the Licensed Enzo Patent Rights.
The Enzo Releasing Parties also release the Illumina Released Persons from any Claim related to the Litigation or the conduct of
settlement negotiations for the Litigation (except for representations or obligations expressly included in this Agreement). The
Enzo Releasing Parties further provide a limited release to Illumina’s Related Persons for any Claim, based on conduct occurring
up to the Effective Date, for infringement of the Licensed Enzo Patent Rights by Illumina Products or Covered Third Party Products.

 

The scope
of this release is fixed as of the Effective Date. Except as expressly set forth herein, this release shall not apply to any Person,
including without limitation any Third Party, or any pre-acquisition business, assets, or products thereof, acquired by Illumina
or its Affiliates (whether by merger, consolidation, share acquisition, or acquisition of all or substantially all assets or otherwise)
after the Effective Date.

 

2.3 Limited
Enzo Covenant Not To Sue On Covered Third Party Products. Subject to the terms and conditions hereof, including Illumina’s
timely payment of the Payment under Section 3.1, Enzo, on behalf of itself and its Affiliates, covenants during the term of this
Agreement not to sue Illumina’s Related Persons for (i) infringement of the Licensed Enzo Patent Rights by an Illumina Product,
or (ii) infringement of the Licensed Enzo Patent Rights by a Covered Third Party Product. This covenant not to sue is non-assignable
by Illumina, its Affiliates or any of their respective Related Persons who benefit from this covenant not to sue.

 

2.4 Illumina
Release of Enzo. Subject to the terms and conditions hereof, Illumina, on behalf of itself, its Affiliates, and their
respective legal successors and assigns (collectively, “Illumina
Releasing Parties”) hereby releases, acquits and absolutely and forever discharges Enzo and its Affiliates (collectively,
“Enzo Released Persons”)
of and from any and all Claims, whether now known or unknown, related to the Licensed Enzo Patent Rights to the extent occurring
before the Effective Date. The Illumina Releasing Parties also release the Enzo Released Persons from any Claim related to the
Litigation or the conduct of settlement negotiations for the Litigation (except for representations or obligations expressly included
in this Agreement).

 

2.5 Covenant
Not to Challenge. After the Effective Date and for so long as Illumina’s license is in force, Illumina further
covenants on behalf of itself and its Affiliates that, except as (i) required by law or (ii) in defense of an action for infringing
the Licensed Enzo Patent Rights brought against Illumina, its Affiliates or their respective Related Persons (direct or indirect)
involving any Illumina Products or Covered Third Party Products, neither Illumina nor its Affiliates shall knowingly and voluntarily
contest (or assist in the contest) in any forum, including Federal Courts, whether under 28 U.S.C. §§ 2201-2202 or not,
the United States Patent and Trademark Office, and/or the International Trade Commission, that the Licensed Enzo Patent Rights
are valid and enforceable; provided, however, nothing in this Agreement shall prevent Illumina or its Affiliates from complying
with or responding to any court or governmental order or subpoena relating to the Licensed Enzo Patent Rights. Notwithstanding
the foregoing, nothing in this Agreement will preclude Illumina and its Affiliates from making

 

	

REVIEWED
BY LEGAL

Initials: RHS

Date: 6/29/16

ILLUMINA

	 

 

	5	SUBJECT TO FRE 408

    	 

    	

    

any disclosure,
providing information or producing documents as required by law, court order or legal process (including, without limitation, litigation
related to discovery and/or subpoena), even if made in connection with a Claim challenging the validity or enforceability of one
or more of the Licensed Enzo Patent Rights, and any such disclosure will not be considered a breach of this Agreement. It is understood
that Illumina’s and its Affiliates’ providing factual statements regarding Illumina Products or any Covered Third Party
Products in response to a validly propounded subpoena will not be considered as assisting in the context as used above. Illumina
reserves the right to raise any and all defenses and counterclaims, including, but not limited to, invalidity and unenforceability
of the Licensed Enzo Patent Rights, and to otherwise contest the validity and enforceability of the Licensed Enzo Patent Rights
in any forum, that it could have raised in the Litigation, if the Licensed Enzo Patent Rights are asserted based on Illumina Products
or Covered Third Party Products against Illumina, its Affiliates, Related Persons and partners after the Effective Date; and Enzo
reserves the right to raise any and all claims and defenses in opposition.

 

2.6 Limited
Standstill. Subject to the terms and conditions in this Section 2.6 and Section 2.7, for a period of four (4) years
after the Effective Date of this Agreement or until the termination of this Agreement under Section 4.2, whichever is earlier (“Standstill
Period”), a Party shall not (either by itself or through an Affiliate or Third Party) initiate, file, encourage,
direct, fund or otherwise bring or participate in any claim alleging infringement (direct, indirect, induced, contributory or otherwise),
misuse or any other violation of any patents against the other Party or its Affiliates by any Standstill Covered Products (the
“Standstill”). “Standstill
Covered Products” are (i) any products or services first made, used, sold, offered for sale, imported or otherwise
commercialized by that Party or its Affiliates on or before the Effective Date, including, without limitation, with respect to
Illumina, the Illumina Products, (ii) any products or services made or sold by such Party or its Affiliates that such Party or
its Affiliates officially announced at an industry conference or other public forum before the Effective Date as part of such Party’s
or its Affiliates’ forthcoming product or service offerings, and (iii) any Natural Evolutions of a product or service covered
by (i) or (ii).

 

In addition,
as part of the Standstill, and subject to the terms and conditions in this Section 2.6 and Section 2.7, during the Standstill Period,
a Party shall not (either by itself or through an Affiliate or Third Party) initiate, file, encourage, direct, fund or otherwise
bring or participate in any claim alleging infringement of any patents against any customer (direct or indirect) of the other Party
or its Affiliates by (i) any commercial products or commercial services first made or sold by that Party or its Affiliates on or
before the Effective Date, or (ii) any commercial products or commercial services made or sold by that Party that such Party or
its Affiliates officially announced at an industry conference or other public forum before the Effective Date as part of such Party’s
or its Affiliates’ forthcoming product or service offerings , or (iii) any Natural Evolutions of a product or service covered
by (i) or (ii) (collectively, “Customer
Standstill Products”). Notwithstanding anything to the contrary herein, Customer Standstill Products do not include,
and expressly exclude, stand-alone Third Party products that infringe a Party’s patents independent of any incorporation
in or use with the other Party’s commercial products or commercial services covered by (i) or (ii) above. For clarity, customers
are protected from claims of infringement under the Standstill only with respect to such customers’ use or resale of Customer
Standstill Products, either alone or as a component or element of such

 

	

REVIEWED
BY LEGAL

Initials: RHS

Date: 6/29/16

ILLUMINA

	 

 

	6	SUBJECT TO FRE 408

    	 

    	

    

customer’s
products or services, but in the latter case only to the extent that any claim of infringement regarding such customer’s
products and/or services is based on the Customer Standstill Product(s) incorporated in such customer’s products or services.

 

The Standstill
shall not apply to and expressly excludes intellectual property rights that claim or cover NIPT and (i) claim priority to a patent
or patent application that, as of the Effective Date, is owned or controlled by Illumina or any of its Affiliates that are existing
and qualify as Affiliates as of the Effective Date or (ii) are subject to the Pooled Patents Agreement between Illumina and Sequenom,
Inc. Notwithstanding the foregoing, in the event Illumina (either by itself or through an Affiliate) initiates, files, directs
or otherwise brings any claim against Enzo, Enzo’s Affiliates that are existing and qualify as Affiliates as of the Effective
Date, or their respective customers (direct or indirect) with respect to the Standstill Covered Products, alleging infringement
(direct, indirect, induced, contributory or otherwise), misuse or any other violation of any intellectual property rights claiming
or covering NIPT, the Parties agree that this will end the Standstill Period with respect to intellectual property rights claiming
or covering NIPT.

 

The Standstill
shall not apply to and expressly excludes any intellectual property rights that claim or cover (i) Liquid Phase Nucleic Acid Amplification
Detection Technologies, or (ii) Cellular Analysis Technologies. For the avoidance of doubt, all Illumina accused products, manufactured
articles, services, processes, systems, or methods that were the subject of the Litigation, and all other products, services, systems,
assays, components, subassemblies, kits, hardware, software, or combinations of the foregoing made or sold by Illumina or its Affiliates
on or before the Effective Date and used in Illumina’s sequencing or array workflows (excluding stand-alone Third Party products
that infringe Enzo patents independent of any incorporation in or use with Customer Standstill Products), are included within the
scope of the Standstill and, for purposes of this Agreement, are by definition not Liquid Phase Nucleic Acid Amplification Detection
Technologies or Cellular Analysis Technologies. Notwithstanding the foregoing, in the event Enzo (either by itself or through an
Affiliate) initiates, files, directs or otherwise brings any claim against either Illumina, Illumina’s Affiliates that are
existing and qualify as Affiliates as of the Effective Date with respect to the Standstill Covered Products, or their respective
customers (direct or indirect) with respect to the Customer Standstill Products, alleging infringement (direct, indirect, induced,
contributory or otherwise), misuse or any other violation of any intellectual property rights claiming or covering either (i) Liquid
Phase Nucleic Acid Amplification Detection Technologies or (ii) Cellular Analysis Technologies, the Parties agree that this will
end the Standstill Period with respect to intellectual property rights claiming or covering either (i) Liquid Phase Nucleic Acid
Amplification Detection Technologies or (ii) Cellular Analysis Technologies.

 

Each Party
hereby expressly waives and agrees to waive damages for any claims of infringement of intellectual property rights included in
the Standstill through the expiration of the Standstill Period. Each Party shall be entitled to seek damages for any claims of
infringement based on conduct occurring after the expiration of the Standstill Period, even if such conduct is identical in nature
to conduct that occurred before the expiration of the Standstill Period.

 

The foregoing
provisions of this Section 2.6 are personal to the Parties and their respective Affiliates (but, as to Affiliates, only personal
to any such Affiliates that are existing and qualify

 

	

REVIEWED
BY LEGAL

Initials: RHS

Date: 6/29/16

ILLUMINA

	 

 

	7	SUBJECT TO FRE 408

    	 

    	

    

as Affiliates
of a Party as of the Effective Date), are non-assignable (including through acquisition), and do not apply to any other Person.
Further, these provisions shall not prevent either Party from engaging in discussions with the other Party or any other Person
regarding the licensing of its patents or from enforcing its patents against any Person other than a Party, its Affiliates, and/or
their respective customers as expressly set forth in this Section 2.6.

 

If either
Party violates this Standstill, the other Party shall be free to immediately end the Standstill Period. If a complaint for patent
infringement based on conduct occurring after the expiration of the Standstill Period is filed after expiration of the Standstill
Period, no Party may rely on the Standstill Period as a basis for any claim, counterclaim, or defense, including without limitation
an assertion of laches. Notwithstanding the foregoing, a Party still may assert any claim, counterclaim, or defense available,
including without limitation an assertion of laches, to the extent it does not specifically rely on the Standstill Period as a
basis.

 

Except with
respect to Customer Standstill Products, for purposes of this Agreement, none of the following Persons (nor their Affiliates and/or
successors) shall be deemed subject to the Standstill set forth in this section for so long as any patent infringement litigation
or royalty obligation existing as of the Effective Date remains pending between Enzo and that Person (or any Affiliate of that
Person): Abbott Laboratories; Abbott Molecular, Inc.; Becton, Dickinson and Company; Becton, Dickinson Diagnostics, Inc.; Geneohm
Sciences, Inc. (now part of Becton Dickinson); Gen-Probe, Inc. (now part of Hologic, Inc.); Hologic, Inc.; Roche Molecular Systems,
Inc. (part of Hoffmann-La Roche AG); Roche Diagnostics Corporation (part of Hoffmann-La Roche AG); Roche Diagnostics Operations
Inc. (part of Hoffmann-La Roche AG); and Roche Nimblegen, Inc. (part of Hoffmann-La Roche AG); or any Third Party that is directly
or indirectly controlling, controlled by, or under common control with any of the foregoing Person.

 

2.7 Acquisitions.
Notwithstanding anything to the contrary above, the licenses, releases, covenants, and Standstill set forth above shall exclude
any pre-acquisition products (and Natural Evolutions thereof following the date of the acquisition) of another Person that acquires
or is acquired by (whether by merger, consolidation, share acquisition, acquisition of all or substantially all assets or otherwise)
a Party (or any other Person that is directly or indirectly controlling, controlled by, or under common control with such Party)
on or after the Effective Date. The Standstill set forth above shall not apply to any action or lawsuit in which the acquired Person
is a party and that is pending as of the date of the public announcement of the acquisition of the acquired Person.

 

2.8 Modifications
and Combinations In Manner Other Than Ordinary Course. No license or immunity is granted under this Agreement by Enzo,
either directly or by implication, estoppel, or otherwise, to any Person acquiring Illumina Products for the modification or combination
by such Person of Illumina Products with other items other than (i) in the ordinary and intended manner in the ordinary course
of use of Illumina Products, (ii) as specified by Sections 2.2 and 2.3, or (iii) as otherwise permitted by the law of patent exhaustion.

 

2.9 No
Extinguishment Of Other Outstanding Royalty Obligations. For the avoidance of doubt, nothing in this Agreement shall
operate to extinguish the obligation of any Person to pay

 

	

REVIEWED
BY LEGAL

Initials: RHS

Date: 6/29/16

ILLUMINA

	 

 

	8	SUBJECT TO FRE 408

    	 

    	

    

royalties
to Enzo or Illumina arising from an obligation outside of this Agreement (including via contract, operation of law, judicial ruling,
or otherwise).

 

2.10 No
Other Rights. No rights or covenants are granted under any patents except as expressly provided herein, whether by implication,
estoppel or otherwise. Except as expressly provided herein, no right to grant covenants, rights, sublicenses, or to become a foundry
for Third Parties is granted under this Agreement. The Parties agree that, except as expressly set forth herein for Covered Third
Party Products and Customer Standstill Products, the licenses, releases and covenants set forth in this Agreement (including Section
2) expressly exclude any methods, systems, products, services and/or components of any Third Party. The Parties further agree that,
except as expressly provided herein for Covered Third Party Products and Customer Standstill Products, this Agreement does not
cut off Enzo’s rights to enjoin, control or extract royalties with respect to such Third Party’s methods, systems,
products, services and/or components.

 

SECTION
3: MONETARY CONSIDERATION

 

3.1 Payment.
As partial consideration and total compensation for the release, license, covenant and Limited Standstill under this Agreement
and the dismissal by Enzo of the Litigation hereunder, Illumina agrees to pay to Enzo a one-time total payment of twenty-one million
U.S. Dollars ($21,000,000.00) (“Payment”),
payable by Illumina to Enzo no later than seven (7) business days following the Effective Date of this Agreement in lawful money
of the United States, in immediately available funds, by wire transfer to the following account:

 

Bank: Citibank,
N.A.

Bank Address:
666 5th Avenue, New York, NY 10103

 

Routing
No.: 021000089

Int’l
Wires: (Swift) CITIUS33

Account
Name: Desmarais LLP IOLA

Account
No.: 9981486845

 

3.2 Taxes
/ Costs. Each Party acknowledges that this Agreement may have U.S. federal and state tax (collectively, “Tax”)
or other consequences, and that the Party is not relying on any other Party for advice, representations or communications as to
any potential Tax or other consequences. This Agreement is enforceable regardless of its Tax or other consequences. The Parties
agree that they shall bear their own costs and attorneys’ fees relating to or arising from the Litigation and to the documentation
and negotiation of this Agreement. Enzo is solely responsible for its own Tax liability, if any, resulting from this Agreement.

 

3.3 Dismissal.
Within three (3) court days after the Payment of the consideration to Enzo under this Section 3 has cleared, the Parties shall
cause their respective counsel to execute and file the stipulated motion in the form set forth in Exhibit
A dismissing with prejudice all of Enzo’s Claims against Illumina in the Litigation. The Parties shall promptly
proceed with any and all additional procedures needed to dismiss the Litigation as set forth above, with each Party to bear its
own costs and attorneys’ fees. The Parties also agree to submit to the court appropriate stipulations and proposed orders
for extensions of time for all due dates in the Litigation so that

 

	

REVIEWED
BY LEGAL

Initials: RHS

Date: 6/29/16

ILLUMINA

	 

 

	9	SUBJECT TO FRE 408

    	 

    	

    

neither
Party is required to incur unnecessary expenses in the Litigation between the Effective Date and the date the Litigation is dismissed.
The Parties acknowledge and agree that this Agreement is enforceable according to its terms with respect to final dismissal with
prejudice of all Claims in the Litigation.

 

3.4 No
Admission of Liability. This Agreement is the result of a compromise and settlement for the purpose of avoiding the
expense, inconvenience, and uncertainty of additional or continued litigation, and will not at any time be considered as an admission
of liability or responsibility, or lack thereof, on the part of Enzo or Illumina. By entering into this Agreement, neither Illumina
nor any of its Affiliates is conceding that it acted wrongfully in any fashion whatsoever. Except as expressly set forth in Section
3.1, Illumina and its Affiliates expressly deny that they are liable to Enzo in any way.

 

3.5 Total
Compensation / Full Settlement. The Parties agree that this Agreement is in full and complete settlement of the rights
and obligations of the Parties in connection with the Litigation. This Agreement may be pleaded as a defense to any action, suit
or claim and may be used as a basis for an injunction against any such action, suit, claim, or other proceeding of any type which
may be prosecuted, initiated or attempted in violation of the terms hereof. A prevailing Party is entitled to recover from the
other adverse Party its reasonable attorneys’ fees and other related legal expenses incurred in defending against any suit,
action or claim brought or attempted by the other Party in violation of the terms of this Agreement.

 

3.6 Maintenance
Fees and Annuities. Enzo, at its expense, shall pay all maintenance fees and/or annuities for all issued patents within
the Licensed Enzo Patent Rights (that are not currently expired) and shall otherwise maintain all such issued patents.

 

SECTION
4: TERM AND TERMINATION

 

4.1 Term.
The term of this Agreement shall commence upon the Effective Date and shall continue until the expiration of the enforceability
period of the last to expire patents within the Licensed Enzo Patent Rights, unless earlier terminated as set forth in Section
4.2 below.

 

4.2 Termination.
If Illumina fails to make the Payment set forth in Section 3.1 in the time frame required by Section 3.1, then Enzo may terminate
this Agreement immediately upon further written notice to that effect and the license, releases, and covenants granted by Section
2 of this Agreement shall immediately terminate, be deemed null and void ab
initio, and be of no force and effect. The licenses, covenants, and releases set forth in this Agreement are effective
as of the Effective Date and may only be terminated if Illumina fails to make the timely Payment as set forth in Section 3.1 above.
The Limited Standstill set forth in Section 2.6 is effective as of the Effective Date and may only be terminated (i) if Illumina
fails to make the timely Payment as set forth in Section 3.1 above, or (ii) as set forth in Section 2.6.

 

SECTION
5: ASSIGNMENT

 

5.1 Assignment.
Except as otherwise permitted in this Section, Illumina may not assign, delegate, or otherwise transfer this Agreement or any license
or rights hereunder without the

 

	

REVIEWED
BY LEGAL

Initials: RHS

Date: 6/29/16

ILLUMINA

	 

 

	10	SUBJECT TO FRE 408

    	 

    	

    

prior written
consent of Enzo. The limitations on assignment set forth in this Section 5 do not apply to an internal reorganization of a Party
or its Affiliates (e.g., re-incorporation or the like). Any other purported assignment, delegation, or transfer without the prior
written consent of Enzo will be null and void ab
initio and without effect. Except as expressly provided for in Sections 2.3 and 2.6, nothing herein expressed or implied
will give or be construed to give any Third Party any legal or equitable rights hereunder.

 

5.2 Permitted Assignment by Illumina.
Notwithstanding the provisions of Section 5.1, Illumina may assign its rights under this Agreement, in whole or in part, without
Enzo’s prior written or oral consent, to a Person with whom Illumina is merged or consolidated, or who acquires all or substantially
all of Illumina’s array or sequencing product lines subject to the Litigation; provided however, that (i) any such assignment
of rights will not extend to products or services of such Person that pre-existed the acquisition (or to Natural Evolutions thereof
following the date of acquisition); and (ii) any such assignment of rights shall not relieve such Person from any obligations
that such Person may have under this Agreement or to Enzo outside of this Agreement. Any assignment or other transfer by Illumina,
or any of its Affiliates, of any rights under this Agreement to any other Person shall be subject in writing to this Agreement
and a written acknowledgment and agreement that the assignee or other transferee shall be bound by such releases and other rights
and covenants. In the event that Illumina does not continue to exist as a distinct operating entity (such as a wholly-owned subsidiary)
after the transaction, the rights of Illumina hereunder so assigned only extend to Illumina Products and Covered Third Party Products
existing as of the date of the transaction and Natural Evolutions of Illumina Products and Covered Third Party Products created
after the date of the transaction, and will not otherwise extend to any products, services, or activities of the Person prior
to, on or after the date of the transaction. The releases and covenants provided by Illumina and its Affiliates to Enzo and its
Affiliates under this Agreement shall run with the rights being assigned or transferred by Illumina and its Affiliates pursuant
to this Section 5.2 and shall be binding on any permitted successors-in-interest, transferees, or assigns thereof. For avoidance
of doubt, any such assignment of rights will not extend to any Third Party products or services existing prior to the time of
transaction or Natural Evolutions thereof. Any purported assignment, delegation, or transfer under this Section 5.2 that does
not comply with the foregoing will be null and void ab
initio and without effect.

 

5.3 Further Restriction on Assignment
by Illumina: Notwithstanding the provisions of Sections 5.1 and 5.2, in no event may this Agreement, including the license,
covenants, and rights granted hereunder, be assigned, delegated, or otherwise transferred without Enzo’s prior written consent
to any of the following: Abbott Laboratories; Abbot Molecular, Inc.; Becton, Dickinson and Company; Becton, Dickinson Diagnostics,
Inc.; Geneohm Sciences, Inc. (now part of Becton Dickinson); Gen-Probe, Inc. (now part of Hologic, Inc.); Hologic, Inc.; Roche
Molecular Systems, Inc. (part of Hoffmann-La Roche AG); Roche Diagnostics Corporation (part of Hoffmann-La Roche AG); Roche Diagnostics
Operations Inc. (part of Hoffmann-La Roche AG); and Roche Nimblegen, Inc. (part of Hoffmann-La Roche AG); or any of the respective
Affiliates of any of the foregoing (each a “Restricted Entity”), so long as any patent infringement litigation
(instituted as of the Effective Date) remains pending between Enzo and the respective aforementioned Restricted Entities. For
the avoidance of doubt, a Restricted Entity’s acquisition of Illumina by stock purchase, reverse triangular merger, or similar
transaction does not

 

	

REVIEWED
BY LEGAL

Initials: RHS

Date: 6/29/16

ILLUMINA

	 

 

	11	SUBJECT TO FRE 408

    	 

    	

    

constitute
an assignment of the Agreement by Illumina where Illumina (or its successor entity) continues to exist as a distinct operating
entity (for example, as a wholly-owned subsidiary of the Restricted Entity) after the date of the acquisition, and the licenses,
covenants, and releases granted herein shall extend only to Illumina Products and Covered Third Party Products existing as of the
date of the acquisition (and Natural Evolutions thereof) and will not otherwise extend to any products, services, or activities
of the acquiring Restricted Entity prior to, on or after the date of the acquisition.

 

5.4 Permitted Assignment by Enzo.
All releases, licenses and other rights and covenants contained herein shall run with and burden the Licensed Enzo Patent Rights
and other intellectual property described in Section 2.6, as it applies to the releases, license and other rights and covenants
contained in Sections 2.1 through 2.6, inclusive, and shall also be binding on any successors-in-interest or assigns thereof.
Any assignment or other transfer of any of the Licensed Enzo Patent Rights to any other Person shall be subject in writing to
this Agreement and a written acknowledgment and agreement that the assignee or other transferee shall be bound by such releases,
licenses and other rights and covenants. Any purported assignment, delegation, or transfer under this Section 5.4 that does not
comply with the foregoing will be null and void ab
initio and without effect.

 

SECTION
6: MISCELLANEOUS PROVISIONS

 

6.1 Representations:

 

6.1.1 Representations by Enzo:
Enzo hereby represents and warrants that: (i) as of the Effective Date, Enzo and/or its Affiliates own the Licensed Enzo Patent
Rights, with all substantive rights in and to same, including the exclusive right to grant the license, collect royalties, collect
past, present and future damages, grant the releases and covenants with respect to the Licensed Enzo Patent Rights set forth herein,
and enforce those rights with legal standing; (ii) as of the Effective Date, it has not assigned or otherwise transferred to any
other Person any rights to the Licensed Enzo Patent Rights that would prevent Enzo from conveying the rights, releases and covenants
set forth herein; (iii) there are no liens or other encumbrances on the Licensed Enzo Patent Rights that would prevent Enzo from
entering into this Agreement; (iv) Enzo’s execution of this Agreement and the performance of Enzo’s obligations hereunder
will not violate any agreement, whether oral or written, to which Enzo or its Affiliates is a party; (v) neither Enzo nor any
of its Affiliates has granted, nor will grant, any licenses or other rights, under the Licensed Enzo Patent Rights, that would
conflict with or prevent the rights granted to Illumina and its Affiliates; and (vi) the person executing this Agreement on behalf
of Enzo has the full right and authority to enter into this Agreement on Enzo’s behalf. Notwithstanding the foregoing, if
any of Enzo’s patents are found invalid, this shall not cause a breach of the foregoing representation regarding Enzo or
its Affiliates’ right to grant the license, release, or other rights provided herein.

 

6.1.2 Illumina Representations:
Illumina represents and warrants that: (i) as of the Effective Date, Illumina has the right to grant the releases and covenants
set forth herein; and

 

	

REVIEWED
BY LEGAL

Initials: RHS

Date: 6/29/16

ILLUMINA

	 

 

	12	SUBJECT TO FRE 408

    	 

    	

    

(ii) the
person executing this Agreement on behalf of Illumina has the full right and authority to enter into this Agreement on Illumina’s
behalf.

 

6.1.3 Disclaimer
of Representation. Nothing in this Agreement shall be construed as (i) a representation or warranty by Enzo as to the scope,
validity, or enforceability of any patent; and (ii) a representation or warranty that the manufacture, use, or sale of any products
will not utilize or infringe any intellectual property rights.

 

6.2 Confidentiality. From and after
the Effective Date, neither Party nor its Affiliates shall disclose the existence or terms of this Agreement except:

 

6.2.1 with
the prior written consent of the other Party;

 

6.2.2 to
any governmental body having jurisdiction and specifically requiring such disclosure, but only to the extent that such disclosure
is so required;

 

6.2.3 in
response to a valid document request or subpoena or as otherwise may be required by law, legal process or order of a court, provided
a protective order is in place that limits disclosure of such information to counsel only and the disclosing Party provides the
other Party with written notice at least ten (10) business days prior to disclosure to permit the other Party the opportunity to
object and/or to seek a court-entered protective order or comparable court-ordered restriction, and shall reasonably cooperate
with the other Party in its efforts to obtain that protective order and take all other reasonable actions in an effort to minimize
the nature and extent of such disclosure and obtain confidential treatment to the extent available;

 

6.2.4 for
the purposes of disclosure in connection with the Securities and Exchange Act of 1934, as amended, the Securities Act of 1933,
as amended, and any other reports filed with the Securities and Exchange Commission (expressly including, but not limited to, Form
8K disclosures), or any other filings, reports or disclosures that may be required under applicable laws or regulations, but only
to the extent that such disclosure is required under said applicable laws or regulations;

 

6.2.5 to
a Party’s accountants, legal counsel, tax advisors and other financial and legal advisors and other professional advisors
in their capacity of advising the Party in such matters, subject to obligations of confidentiality and/or privilege at least as
stringent as those contained herein;

 

6.2.6 with
obligations of confidentiality at least as stringent as those contained herein, to a counterparty in connection with a proposed
merger, acquisition, financing or similar transaction;

 

6.2.7 in
connection with tax audits or to fulfill its corporate financial reporting obligations under GAAP;

 

	

REVIEWED
BY LEGAL

Initials: RHS

Date: 6/29/16

ILLUMINA

	 

 

	13	SUBJECT TO FRE 408

    	 

    	

    

6.2.8 with
obligations of confidentiality at least as stringent as those contained herein, by any Party and its Affiliates as required to
enforce this Agreement or establish rights hereunder;

 

6.2.9 to
officers, key shareholders and/or employees with a need to know, attorneys, accountants and directors, who are under obligations
of confidentiality (which may include professional responsibility obligations) at least as stringent as those contained herein;

 

6.2.10 to
its Affiliates, who are similarly bound by this Agreement or under obligations of confidentiality at least as stringent as those
contained herein; and

 

6.2.11 to
Third Parties who make, sell, offer to sell, export, import, distribute or otherwise commercialize any Illumina Product or who
make, sell, offer to sell, export, import, distribute or otherwise commercialize any Covered Third Party Product or Customer Standstill
Product, and who have a need to know, but only to the extent of such need to know and only under obligations of confidentiality
at least as stringent as those contained herein.

 

Notwithstanding
anything else in this Agreement to the contrary, a Party may also disclose to anyone any information that is publicly available
through no breach by that Party or its Affiliates of the confidentiality obligations hereunder.

 

6.3 Notices. All notices required
or permitted to be given hereunder shall be in writing and shall be delivered by hand, or, if dispatched by prepaid air courier,
with package tracing capabilities or by registered or certified airmail, postage prepaid, addressed as follows:

 

If
to Enzo:

 

Dr. Elazar
Rabbani

Enzo Life
Sciences, Inc.

527 Madison
Avenue

New York,
NY 10022

 

Copy to
(which does not constitute notice):

 

Michael
Stadnick

Desmarais
LLP

230 Park
Avenue

New York,
NY 10169

 

If
to Illumina:

 

Illumina,
Inc.

5200 Illumina
Way

San Diego,
California 92122

Attn: General
Counsel

 

	

REVIEWED
BY LEGAL

Initials: RHS

Date: 6/29/16

ILLUMINA

	 

 

	14	SUBJECT TO FRE 408

    	 

    	

    

Copy to
(which does not constitute notice):

 

Craig Countryman

Fish &
Richardson P.C.

12390 El
Camino Real

San Diego,
California 92130

 

Such notices
shall be deemed to have been served when received by addressee. Either Party may give written notice of a change of address and,
after notice of such change has been received, any notice or request shall thereafter be given to such Party as above provided
at such changed address.

 

6.4 Publicity. Neither Party will
issue a press release or any other public announcement regarding this Agreement or the settlement of the Litigation unless the
other Party provides prior consent in writing. Notwithstanding the foregoing and Section 6.2 above, upon inquiry either Party
may state that Enzo and Illumina have entered into a settlement agreement.

 

6.5 Governing Law / Jurisdiction.
This Agreement and matters connected with the performance thereof shall be construed, interpreted, applied and governed in all
respects in accordance with the laws of the United States of America and the State of Delaware, without reference to conflict
of laws principles. Enzo and Illumina agree (a) that all disputes and litigation regarding this Agreement, its construction and
matters connected with its performance be subject to the exclusive jurisdiction of the state and federal courts in the District
of Delaware (the “Court”), and (b) to submit any disputes, matters of interpretation, or enforcement actions
arising with respect to the subject matter of this Agreement exclusively to the Court. The Parties hereby waive any challenge
to the jurisdiction or venue of the Court over these matters.

 

6.6 Sophisticated Parties Represented
by Counsel. Each Party warrants and represents that (i) it is a sophisticated party represented at all relevant times during
the negotiation and execution of this Agreement by counsel of its choice, and that it has executed this Agreement with the consent
and on the advice of such independent legal counsel; (ii) it and its counsel have determined through independent investigation
and robust, arm’s-length negotiation that the terms of this Agreement shall exclusively embody and govern the subject matter
of this Agreement, (iii) it investigated the facts pertinent to this Agreement as it deemed necessary, (iv) no other Person or
Party, nor any agent or attorney of a Party, made any promise, representation or warranty whatsoever, express or implied, not
contained in this Agreement concerning the subject matter of this Agreement to induce it to execute this Agreement, (v) it has
not executed this Agreement in reliance on any promise, representation or warranty whatsoever, express or implied, not contained
in this Agreement concerning the subject matter of this Agreement, and (vi) it has not executed this Agreement in reliance on
any promise, representation or warranty not contained herein. The Parties included this paragraph to preclude any claim that any
Party was fraudulently induced to execute this Agreement and to preclude the introduction of parol evidence to vary, interpret,
supplement or contradict the terms of this Agreement.

 

6.7 Bankruptcy. The Parties acknowledge
and agree that all releases, rights, covenants and licenses granted by Enzo under or pursuant to this Agreement, including the
Limited Standstill in

 

	

REVIEWED
BY LEGAL

Initials: RHS

Date: 6/29/16

ILLUMINA

	 

 

	15	SUBJECT TO FRE 408

    	 

    	

    

Section 2.6, are, and will otherwise be
deemed to be, for purposes of Section 365(n) of the United States Bankruptcy Code, as amended (the “Bankruptcy Code”),
rights of and to “intellectual property” as defined under Section 101 of the Bankruptcy Code. The Parties agree that,
notwithstanding anything else in this Agreement, Illumina and its Affiliates, as the licensee or recipients of such intellectual
property rights under this Agreement, will retain and may fully exercise all of its rights and elections under the Bankruptcy
Code (including, without limitation, Illumina and its Affiliates’ right to the continued enjoyment of the rights and licenses
granted by Enzo under this Agreement). Notwithstanding the foregoing, this Agreement shall be deemed and treated as an executory
contract under Section 365 of the Bankruptcy Code and is subject to the restrictions on assumption and assignment in Section 365(c).
Further, this provision shall not alleviate or contravene the restrictions on assignments and acquisitions set forth in this Agreement.

 

6.8 No
Laundering. The Parties understand and acknowledge that the licenses, releases, and covenants granted to Illumina and its Affiliates
by Enzo hereunder are intended to cover only the bona fide products and services of Illumina, its Affiliates and their respective
Related Persons and are not intended to cover patent laundering activities (i.e., activities that are undertaken solely for the
purpose of improperly extending licensed and other rights to cover any activity of any Third Party acting outside the scope of
Illumina’s, its Affiliates’, or their respective Related Persons’, licensed and otherwise covered activities).
The Parties further agree that a purchase of a product from a supplier and resale of such product in substantially the same form
back to the same supplier is not licensed under this Agreement. Nothing in this Agreement shall be construed to license sham sales
or sham service contracts executed by Illumina or any of its Affiliates with any Third Party solely for the purpose of improperly
extending licensed rights to cover any activity of any Third Party acting outside the scope of Illumina’s (or its Affiliates’)
licensed or otherwise covered activities.

 

6.9 Severability.
If any provision of this Agreement is held to be invalid, illegal or unenforceable, such provision shall be limited or eliminated
to the minimum extent necessary so that the remainder of this Agreement will continue in full force and effect and be enforceable.
The Parties agree to negotiate in good faith an enforceable substitute provision for any invalid, illegal or unenforceable provision
that most nearly achieves the intent of such provision.

 

6.10 Entire
Agreement. The Parties hereby agree that (i) this is an enforceable agreement; (ii) this Agreement constitutes the entire
and only understanding of each of them with respect to the subject matter of the Agreement, and merges, supersedes and cancels
all previous agreements and understandings, whether oral or written, with respect to the subject matter of the Agreement; (iii)
no oral explanation or oral information by any Party hereto shall alter the meaning or interpretation of this Agreement; (iv) the
terms and conditions of this Agreement may be altered, modified, changed or amended only by a written agreement that identifies
itself as an amendment to this Agreement and is executed by duly authorized representatives of each of them; (v) the language of
this Agreement has been approved by counsel for each of them, and shall be construed as a whole according to its fair meaning;
and (vi) none of the them (nor their respective counsel) shall be deemed to be the draftsman of this Agreement in any action which
may hereafter arise with respect to the Agreement.

 

	

REVIEWED
BY LEGAL

Initials: RHS

Date: 6/29/16

ILLUMINA

	 

 

	16	SUBJECT TO FRE 408

    	 

    	

    

6.11 Modification;
Waiver. No modification or amendment to this Agreement, nor any waiver of any rights, will be effective unless assented to
in writing by the Party to be charged, and the waiver of any breach or default will not constitute a waiver of any other right
hereunder or any subsequent breach or default.

 

6.12 Construction;
Language. Any rule of construction to the effect that ambiguities are to be resolved against the drafting Party will not be
applied in the construction or interpretation of this Agreement. As used in this Agreement, the words “include” and
“including” and variations thereof, will not be deemed to be terms of limitation, but rather will be deemed to be followed
by the words “without limitation.” The terms “will” and “shall” are used synonymously. The
headings in this Agreement will not be referred to in connection with the construction or interpretation of this Agreement. This
Agreement is in the English language only, which language shall be controlling in all respects, and all notices under this Agreement
shall be in the English language.

 

6.13 Counterparts.
This Agreement may be executed in counterparts or duplicate originals, both of which shall be regarded as one and the same instrument,
and which shall be the official and governing version in the interpretation of this Agreement. This Agreement may be executed by
facsimile signatures or other electronic means and such signatures shall be deemed to bind each Party as if they were original
signatures.

 

6.14 Further
Assurances. Each Party shall execute, acknowledge and deliver such further documents and instruments and perform such other
acts as may be necessary or appropriate in order to carry out the purposes and intent of this Agreement.

 

	

REVIEWED
BY LEGAL

Initials: RHS

Date: 6/29/16

ILLUMINA

	 

 

	17	SUBJECT TO FRE 408

    	 

    	

    

IN WITNESS
WHEREOF, the Parties hereto have caused this Agreement to be signed below by their respective duly authorized officers.

 

Enzo Life Sciences, Inc.

 

	By:	/s/
    Dr. Elazar Rabbani	 
	 	 	 
	Name:  	Dr. Elazar Rabbani	 
	 	 	 
	Title:	Chief Executive Officer	 
	 	 	 
	Date:	July 1, 2016	 

 

Illumina,
Inc.

 

	By:	/s/
    Francis deSouza	 
	 	 	 
	Name:  	Francis deSouza	 
	 	 	 
	Title:	President	 
	 	 	 
	Date:	6/29/16	 

 

	

REVIEWED
BY LEGAL

Initials: RHS

Date: 6/29/16

ILLUMINA

	 

 

	18	SUBJECT TO FRE 408

    	 

    	

    

EXHIBIT
A

 

STIPULATED
MOTION FOR DISMISSAL OF LITIGATION

 

UNITED
STATES DISTRICT COURT

OF DELAWARE

 

	ENZO LIFE SCIENCES, INC.	)	CASE NO. CV 12-CV-435-LPS
	 	)	JOINT STIPULATION OF DISMISSAL 

WITH PREJUDICE
	Plaintiff,	)
	vs.	)
	)	The Hon. Leonard Stark
	ILLUMINA, INC.	)	Chief United States District Court Judge
	 	)	 
	Defendant.	)	 
	 	)	 

 

Pursuant
to Rule 41(a)(1)(A)(ii) of the Federal Rules of Civil Procedure, Plaintiff, Enzo Life Sciences, Inc., and Defendant, Illumina,
Inc., by and through their respective counsel, hereby stipulate to the dismissal with prejudice of all claims in this action. Each
party shall bear its own attorneys’ fees and costs.

 

	Respectfully submitted,	 	 	 
	 	 	 	 
	 	 	 	FISH & RICHARDSON P.C.
	 	 	 	 
	FARNAN LLP	 	 	 
	 	 	 	 
	 	 	 	By:   	 
	
        Brian E. Farnan
        (#4089)

        919 North Market Street, 12th Flr

        Wilmington, DE 19801

        (302) 777-0336

        bfarnan@farnanlaw.com

         

        Attorneys for
        Plaintiff

        Enzo Life Sciences, Inc.
        

        

         

        Of Counsel:

        

         

        John M. Desmarais
        (admitted pro hac vice)

	 	 	 

    	 

    	

    

	
        Michael P.
        Stadnick (admitted pro hac vice)

        Justin P.D. Wilcox (admitted pro hac vice)

        Jordan N. Malz (admitted pro hac vice)

        Peter C. Magic (admitted pro hac vice)

        Desmarais LLP

        230 Park Avenue

        New York, NY 10169

        (212) 351-3400 (Tel)

        (212) 351-3401 (Fax)

        jdesmarais@desmaraisllp.com

        mstadnick@desmaraisllp.com

        jwilcox@desmaraisllp.com

        jmalz@desmaraisllp.com

        pmagic@desmaraisllp.com

         

        Attorneys
        for Plaintiff

        Enzo Life Sciences, Inc.

         
	 	
        Douglas E.
        McCann (#3852)

        Martina Tyreus Hufnal (#4771)

        Kelly Allenspach Del Dotto (#5969)

        222 Delaware Avenue, 17th Floor

        Wilmington, DE 19801

        (302) 652-5070

        dmccann@fr.com

        hufnal@fr.com

        allenspach.del.dotto@fr.com

         

        Juanita Brooks

        Michael A. Amon

        Craig Countryman

        Robert M. Yeh

        Markus Weyde

        FISH & RICHARDSON P.C.

        12390 El Camino Real

        San Diego, CA 92130

        Phone: 858-678-5070

        brooks@fr.com; amon@fr.com;

        countryman@fr.com; yeh@fr.com;

        weyde@fr.com

         

        Attorneys
        for Defendant

        Illumina, Inc.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00263-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00263-of-00352.parquet"}]]